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 Upon infecting a host, viruses immediately face restriction by the host immune 
system, including innate and adaptive responses. To mediate efficient replication, viruses 
have evolved a number of mechanisms to subvert and bypass the host immune responses. 
Among the earliest immune protections encountered by viruses are a group of cell-
intrinsic immunity proteins called “restriction factors.” Restriction factors have been 
identified that, if not counteracted, are capable of inhibiting viral replication throughout 
the viral life cycle. One of the primary mechanisms utilized to counteract these 
restrictions is the manipulation of the cellular ubiquitin ligase system to induce the 
directed and specific degradation of these cellular factors. 
In the case of primate lentiviruses (HIVs and SIVs), four proteins (Vif, Vpu, Vpr, 
and Vpx) have been shown to alter the specificity of this cellular degradation machinery 
to target restriction factors. In this study, we explore the molecular interaction between 
the paralogous proteins Vpr (encoded by all primate lentiviruses) and Vpx (encoded by 
HIV-2 and some SIVs), the cellular ubiquitin ligase composed of Cul4-Roc1-DDB1-
DCAF1 and the restriction factors they target for degradation (Mus81 in the case of Vpr 
and SAMHD1 in the case of Vpx). Through mutation of DCAF1, the substrate specificity 
factor for the ubiquitin ligase complex, to which Vpr and Vpx are known to directly 
interact, we show that although they share a high degree of homology, Vpr and Vpx 
interact with DCAF1 differently. In addition, through the generation of chimeric Vpr-
  iv 
Vpx proteins, we explore the molecular determinants of Vpr and Vpx substrate 
specificity. To this end, we demonstrate that manipulation of Cul4-DCAF1 substrate 
specificity by Vpr and Vpx is mediated by nonlinear determinants within the respective 
proteins, in contrast to previously proposed models. Finally, we demonstrate that Vpr 
induces the degradation of Mus81 in a manner independent of the induction of G2 arrest, 













those who will come after.  
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Cell Intrinsic Restriction of Viral Replication 
An introduction to cellular restriction and viral countermeasures 
 Immediately following infection, pathogens begin to interact with immune 
effectors of the host, from the canonical cell-mediated immunity of the innate and 
adaptive immune cells, to the more recently identified cell intrinsic immunity mediated 
by cellular restriction factors. Restriction factors are a broad family of proteins involved 
in sensing and inhibiting the replication of intracellular pathogens. In the context of viral 
infections, restriction factors have been identified that act at every stage along replication 
cycles from uncoating (as exemplified by TRIM5 (reviewed in (Luban, 2012)) and 
limiting the supply of vital building blocks necessary for replication (such as the 
regulation of nucleotide availablity by SAMHD1 (reviewed in (Laguette and Benkirane, 
2012; Schaller et al., 2012)), to recognition of genomes by cellular RNA and DNA 
sensors (reviewed in (Jensen and Thomsen, 2012; O'Neill, 2013)) and inhibiting release 
of new virions from infected cells (by BST-2/tetherin (reviewed in (Dubé et al., 2010)) 
(field reviewed in (Duggal and Emerman, 2012)). 
 Efficient replication in the face of this barrage of cellular restrictions has required 
viruses to evolve mechanisms to subvert these host factors. To this end, viruses utilize a 
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number of strategies, including mutating or hiding molecular motifs recognized by innate 
immune sensors. Perhaps the most ingenious strategy utilized to avoid cellular restriction 
is the manipulation of the cellular ubiquitin proteasome system (UPS) by viruses 
(reviewed in (Randow and Lehner, 2009)). The UPS functions as one of several pathways 
utilized by eukaryotes to regulate protein function through the conjugation of any of a 
highly structurally related class of ubiquitin-like proteins. The UPS serves as a dynamic 
and highly regulated network for modulation of cellular protein dynamics (Ravid and 
Hochstrasser, 2008). 
 To this end, a broad array of viruses have been identified to encode proteins that 
modulate the specificity and activity of the UPS in order to facilitate viral replication 
(Table 1.1). Thus far, viral manipulation has primarily been observed to redirect ubiquitin 
ligases towards the degradation of cellular factors that negatively affect viral replication 
(reviewed in (Randow and Lehner, 2009)); however, given the industrious nature of viral 
manipulation of cellular pathways, future studies will no doubt uncover examples of 
alternative affects of viral ubiquitin ligase hijacking. Primate lentiviruses (HIV/SIV) are 
no exception to this ubiquitin ligase modulation. Indeed, primate lentiviruses are known 
to encode four proteins which alter the substrate specificity of cellular ubiquitin ligases 
(Vif, Vpu, Vpr, and Vpx) (reviewed in (Gramberg et al., 2009; Harris et al., 2012). This 
chapter will focus on our understanding of the functions and differences between the 





Vpr and Vpx: HIV/SIV’s Fraternal Twins  
Vpr the enigma 
 Of the primate lentiviral accessory proteins, the function of Vpr has remained the 
most elusive. Over the three decades since the identification of HIV as the causative 
agent of AIDS, a pleiotropic range of functions has been ascribed to Vpr. Initial reports 
indicated a slower rate of viral replication, in vitro, in viruses lacking Vpr. In addition, 
Vpr has been shown to enhance expression from the viral promoter. These results led to 
the early name: Viral protein regulatory (Vpr)(reviewed in (Guenzel et al., 2014)). Other 
early reports implicated Vpr in mediating nuclear import of the pre-integration complex 
(Heinzinger et al., 1994); however, these observations have been called into doubt and 
have been generally discredited in recent studies of Vpr activity. 
 Perhaps the most investigated aspect of Vpr function is its ability to induce cell 
cycle arrest at the G2/M transition, similar to that observed following DNA damage 
and/or replication stress (Re et al., 1995; Jowett et al., 1995; He et al., 1995; Rogel et al., 
1995)(reviewed in (Andersen et al., 2008)). In 2003, our laboratory determined that Vpr 
induced the activation of the DNA damage sensor ATR and that this activation was 
necessary for Vpr-mediated G2 arrest (Roshal et al., 2003). Subsequent research from our 
lab and others demonstrated Vpr-induced ATR activation mirrored that of DNA 
damaging agents, such as UV irradiation, inducing the phosphorylation RPA32, a protein 
known to “mark” regions of single stranded DNA, as well as downstream mediators 
including Chk1 and Wee1, and the stabilization of Cdk1 (reviewed in (Andersen et al., 
2008)). Interestingly, pulse field gel electrophoresis studies indicated Vpr was not 
inducing double-strand breaks (Lai et al., 2005). In agreement with this observation, 
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expression of Vpr failed to induce the activation of the closely related DNA damage 
sensor ATM or its immediate downstream signaling mediator, Chk2 (Zimmerman et al., 
2004; Lai et al., 2005). 
 While numerous studies had investigated the downstream consequences of Vpr-
induced G2 arrest, it took several years before significant insight into how Vpr was 
activating ATR signaling was achieved. In 1994, Vpr was shown to interact with a 
cellular protein of unknown function, originally named Vpr-Interacting-Protein (RIP or 
VprBP) (ZhaoS et al., 1994). Over a decade later, two groups identified RIP as a member 
of a family of proteins involved in dictating the substrate specificity of the Cullin 4-
DDB1 ubiquitin ligase (DDB1-Cullin 4 Associated Factors, DCAFs) and renamed it 
DCAF1 (Jin et al., 2006; Angers et al., 2006). Soon thereafter, several groups 
demonstrated that induction of G2 arrest by Vpr is dependent on the activity of this 
ubiquitin ligase. Namely, knockdown of components of the ubiquitin ligase or expression 
of Vpr mutants that failed to interact with DCAF1 prevented Vpr induction of G2 arrest 
(Dehart et al., 2007; Le Rouzic et al., 2007; Schröfelbauer et al., 2007; Hrecka et al., 
2007; Wen et al., 2007)(reviewed in (Dehart and Planelles, 2008)). Identifying the 
cellular protein(s) targeted for ubiquitination by Vpr has proven to be difficult. 
 
Vpr and UNG2 
 Perhaps the most studied putative ubiquitination target of Vpr is the Uracil DNA 
Glycosylase (UNG2). In normal cellular physiology, UNG2 serves to repair mis-
incorporated Uracil-deoxyribonuleotide through the catalytic removal of the base from 
the phosphate-sugar backbone, resulting in the generation of an abasic site, which is then 
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repaired via the potentially mutagenic base excision repair (BER) pathway (reviewed in 
(Planelles and Benichou, 2010)). Viral reverse transcription is known to result in the 
incorporation of dUTP into HIV DNA (Kennedy et al., 2011) and it is proposed that 
UNG2-generated abasic sites at these misincorporated uracils may induce hypermutation 
of the viral genome reminiscent of that generated by the APOBEC family of cellular 
restriction factors (reviewed in (Planelles and Benichou, 2010)). 
 Expression of Vpr in cells destabilizes UNG2 in a DCAF1-dependent manner 
(Schröfelbauer et al., 2005). However, this destabilization of UNG2 is not associated with 
the cell cycle phenotype observed during Vpr expression (Selig et al., 1997). Indeed, 
recent reports indicate UNG2 destruction may be a secondary effect of Vpr expression, as 
UNG2 appears to be expressed differentially throughout the cell cycle, with the lowest 
expression levels observed during the G2 phase of the cell cycle (Hagen et al., 2008). 
Intriguingly, the de Noronha lab recently reported UNG2 may itself be an endogenous 
substrate of DCAF1, raising the possibility that a consequence of Vpr manipulation of the 
DCAF1-containing ubiquitin ligase results in a general hyperactivation of the complex 
(Wen et al., 2012). In agreement with this hypothesis, Vpr was observed to induce an 
increased association of DCAF1 with activated Cul4, as measured by the increased 
degree of neddylation of Vpr-associated Cul4 (Hrecka et al., 2007). 
Recent studies, however, have called into question the potential negative 
consequences of UNG2 to viral replication. Selig et al. demonstrated UNG2 is 
incorporated into budding virions in a Vpr-dependent manner (Selig et al., 1997). This 
encapsidation was observed to have a net positive effect on viral infectivity independent 
of UNG2 enzymatic activity (Guenzel et al., 2012). In support of the hypothesis that 
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UNG2 plays a positive role in HIV replication, a siRNA screen of DNA repair proteins 
demonstrated that proteins involved in BER, such as UNG2, but not those of the 
homologous or the nonhomologous end joining pathways, play an important role in viral 
replication (Espeseth et al., 2011). Interestingly, Yan et al. also reported a positive effect 
of incorporation of dUTP into viral reverse transcripts by reducing the rate of 
autointegration of the viral genomes, a replicative dead-end (Yan et al., 2011). Given the 
high concentrations of dUTP in macrophages (Kennedy et al., 2011), the beneficial role 
of UNG2 encapsidation was first observed in HIV infection of macrophages (Chen et al., 
2004). While Chen et al. noted an increased mutation rate in viruses carrying the Vpr 
W54R mutant, which is unable to facilitate UNG2 encapsidation, these viruses were 
severely crippled in their ability to productively infect monocytes-derived macrophages 
(MDMs) from healthy donors (Chen et al., 2004). In addition, Jones et al. noted a HIV-1 
tropism-dependent requirement for UNG2 in viral replication, in which infection by R5 
tropic virus, capable of infecting macrophages, but not X4 tropic virus, was negatively 
affected by UNG2 depletion (Jones et al., 2010). 
 
Vpr and Dicer 
 Though it has previously been shown that HIV infection alters the cellular RNA 
silencing pathways (Yeung et al., 2005), the mechanisms and benefits of this activity 
remained controversial. In 2010, Coley et al. reported a Vpr-dependent reduction of Dicer 
expression in MDMs (Coley et al., 2010); however, it remained unclear if this was a 
direct or indirect effect of Vpr expression in these cells. Subsequently, it was shown that 
this down regulation was mediated by a direct interaction between Vpr and Dicer and 
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dependent on the Cul4-DCAF1 ubiquitin ligase (Casey Klockow et al., 2013). In 
agreement with reports that Dicer depletion does not induce G2 arrest, Klockow et al. 
observe that Vpr-mediated Dicer depletion is not related to the Vpr G2 arrest phenotype 
(Bu et al., 2009; Casey Klockow et al., 2013). Instead, Dicer depletion appears to 
enhance HIV infection of macrophages, though the exact mechanism of this enhancement 
is unclear (Casey Klockow et al., 2013).  
 
 
Vpr and the SLX4-Mus81 Complex 
 Though the induction of cell cycle arrest by Vpr is perhaps the most studied 
aspect of Vpr biology, it has remained the most poorly understood. Recently, Laguette et 
al. reported a putative mechanism for Vpr induction of G2 arrest. By analyzing the serial 
immunoprecipitation of a FLAG/HA-Vpr construct expressed in the monocyte THP-1 
cell line, several members of the SLX4-containing endonuclease complex (SLX4, 
ERCC4, EME1, MUS81, TSPYL1, C20orf94, and ERCC1) were identified by mass 
spectrometry as Vpr interactors (Laguette et al., 2014). Previously, the SLX4 complex 
was identified as a structure-specific endonuclease involved in resolving Holiday 
junctions (reviewed in (Schwartz and Heyer, 2011)). Laguette et al. provide evidence that 
Vpr functions to activate this endonuclease, driving the degradation of HIV reverse 
transcripts. They further show that Vpr expression inhibits the induction of an interferon 
response and that this activity is dependent on SLX4 and Mus81 (Laguette et al., 2014). 
These observations led them to propose a model whereby Vpr activates this endonuclease 
complex to facilitate the degradation of reverse transcripts in order to prevent their 
recognition by cellular DNA sensors such as cGAS (Gao et al., 2013) or IFI-16 
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(Unterholzner et al., 2010). Interestingly, this model closely mirrors observations made in 
regards to the activity of the cytosolic endonuclease TREX1 (Yan et al., 2010). Further, 
Laguette et al. propose this activation to be the biases of the previously reported Vpr-
induced G2 arrest through the inadvertent generation of genomic damage resulting in the 
activation of ATR (Laguette et al., 2014). 
Several observations indicate this activation of the SLX4 complex by Vpr is 
dependent on the manipulation of the Cul4-DCAF1 ubiquitin ligase by Vpr. Specifically, 
wild type (WT) Vpr, but not the DCAF1-interaction-defective Vpr Q65R mutant, is able 
to co-immunoprecipitate SLX4 and Mus81. Additionally, while WT Vpr is able to induce 
poly-ubiquitination of exogenously expressed Mus81, the Vpr Q65R mutant fails to do so 
above background levels. The observations of Laguette et al. point to a unique 
mechanism of UPS manipulation by Vpr in comparison to other viral proteins known to 
modulate the UPS (Table 1). While a slight reduction of Mus81 protein level is observed 
following the expression of Vpr, the activation of the SLX4 does not appear to be 
mediated by the degradation of any of the identified subunits. In fact, depletion of many 
of the SLX4 complex subunits (SLX4, SLX1, EME1, or Mus81) by siRNA inhibit the 
ability of Vpr to induce G2 arrest (Laguette et al., 2014). This is in contrast to previously 
proposed models in which Vpr was hypothesized to induce the aberrant degradation of a 
cellular factor (reviewed in (Andersen et al., 2008)). This model postulates that down 
regulation of this factor would mirror Vpr activity, in contrast to what Laguette et al. 
observed. Additionally, while the manipulation of the UPS by other viral proteins seems 
to generally be directed at overcoming a factor involved in restricting viral replication, 
the Vpr activity reported by Laguette et al. is indirect, inducing the degradation of HIV 
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reverse transcripts to prevent downstream recognition by DNA sensors and the 
subsequent induction of interferon. 
Similar to the recent observations by Wen et al. regarding Vpr-mediated UNG2 
destabilization (Wen et al., 2012), Laguette and colleagues observed interaction of both 
SLX4 and Mus81 with DCAF1 in the absence of Vpr. In addition, Vpr appears to interact 
with the SLX4 complex only in the context of DCAF1 as the Vpr Q65R mutant does not 
interact with either SLX4 or Mus81. The dominant negative Vpr mutant R80A, which 
can interact with DCAF1 but fails to induce G2 arrest, has the ability to interact with 
SLX4 but not Mus81 (Laguette et al., 2014). Taken together, these results point to a 
model whereby Vpr activates the SLX4 complex by hyperactivating the Cul4-DCAF1 
ligase towards an endogenous substrate. 
The observations by Laguette and colleagues raise a number of unresolved 
questions. Vpr is known to be encapsidated within the incoming virion; however, it 
remains unclear if SLX4 complex activation is mediated by incoming or de novo Vpr. 
Although Vpr induced ubiquitination of Mus81, Vpr activation of the SLX4 complex 
activation was also dependent on Plk1 phosphorylation of EME1 (Laguette et al., 2014). 
How Vpr induces this phosphorylation remains unresolved. ATR activation, a hallmark 
of Vpr-induced cell cycle arrest (Roshal et al., 2003), has previously been shown to 
inhibit Plk1 activity (Deming et al., 2002). Additionally, it remains unclear how Vpr 
directs this activity, or if it does, toward unproductive reverse transcription products.  





Vpx facilitates infection of noncycling cells 
 While several classes of noncycling cells, including resting CD4+ T-cells and 
myeloid lineage cells, are known to express the receptors necessary for HIV-1 infection, 
only modest levels of infection of these cells are observed in vivo. In contrast, HIV-2 and 
many SIVs are known to be capable of efficiently infecting these cells (Reviewed in 
(Yamashita and Emerman, 2006; Ayinde et al., 2010)). Initial studies demonstrated that 
this restriction was at the early stages of reverse transcription and was overcome by HIV-
2/SIVs Vpx, present within the infecting virions. Indeed, providing Vpx in trans could 
dramatically increase the efficiency of HIV-1 infection of myeloid cells in vitro (Kaushik 
et al., 2009). 
 In 2011, two groups independently identified sterile alpha motif domain (SAM) 
and histidine/aspartic acid domain (HD) containing protein 1 (SAMHD1) as the cellular 
factor responsible for mediating this restriction (Hrecka et al., 2007; Laguette et al., 
2011a). Utilizing mass spectrometry, both groups identified SAMHD1 as a myeloid cell-
derived Vpx-specific interacting protein. Both groups were then able to show 
encapsidated Vpx was capable of inducing SAMHD1 degradation in target cells, 
facilitating infection with a lentiviral reporter (HIV-LUC-G in the case of Laguette et al. 
2011, or HIV-GFP in the case of Hrecka et al. 2011). These studies were then able to 
demonstrate that SAMHD1 was sufficient for facilitating restriction of lentiviral infection 
of myeloid cells through siRNA-mediated SAMHD1 depletion. 
 Like its paralog, Vpx had previously been shown to manipulate the Cul4-DCAF1 
ubiquitin ligase (Srivastava et al., 2008). In agreement with the hypothesis that Vpx 
facilitated the degradation of a myeloid restriction factor through manipulation of 
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DCAF1 specificity, Hrecka and colleagues observed Vpx-induced SAMHD1 degradation 
was inhibited following siRNA knockdown of DCAF1. In agreement with this 
observation, virus-like particle (VLP) treatment of restricted cells with Vpx Q76A, a 
mutant that has previously been shown to lack DCAF1 interaction (Srivastava et al., 
2008), failed to facilitate HIV-1 GFP infection (Hrecka et al., 2011).  
 
Mechanism of SAMHD1 restriction 
Previously, SAMHD1 had been identified as one of seven genes (TREX1, 
RNASEH2A, RNASEH2B, RNASEH2C, and SAMHD1 (reviewed in (Crow and 
Livingston, 2008)) and ADAR1 (Rice et al., 2012) and MDA5 (Rice et al., 2014) in 
which polymorphisms have been linked to the rare hereditary condition Aicardi-
Goutières Syndrome (AGS). AGS is a generally early onset inflammatory disorder 
characterized by elevated levels of IFN-α in cerebrospinal fluid in the absence of 
infection (Crow and Livingston, 2008), potentially due to elevated activity of 
transposable elements (reviewed in (Planelles, 2011)). The progression of disease is 
reminiscent of chronic viral infection, and its study has led to important insights into the 
genetic factors involved in control of congenital infection (Crow and Livingston, 2008). 
While the mechanism of SAMHD1 restriction of HIV-1 infection was initially 
unclear, several pieces of evidence indicated an involvement in nucleotide metabolism. 
First, all other AGS loci are known to be involved in nucleotide metabolism (Crow and 
Livingston, 2008; Rice et al., 2012; 2014). Secondly, HD domain-containing proteins 
have largely been identified as phosphohydrolases that target nucleotides (reviewed in 
(Planelles, 2011)). Finally, SAMHD1 mediated restriction to HIV replication during 
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reverse transcription (Srivastava et al., 2008). In the years since the identification of 
SAMHD1 as the myeloid restriction factor, several groups have extensively examined the 
metabolic activities of SAMHD1. Soon after the initial reports on SAMHD1 restriction of 
HIV, Goldstone et al. demonstrated that SAMHD1 is a deoxynucleoside triphosphate 
triphosphohydrolase capable of hydrolyzing all dNTP species to deoxynucleoside and 
inorganic triphosphate (Goldstone et al., 2011). SAMHD1 triphosphohydrolase activity is 
tightly linked to cellular dNTP concentrations through an allosteric dGTP binding pocket 
(Goldstone et al., 2011; Amie et al., 2013b) that facilitates SAMHD1 oligmerization (Ji et 
al., 2013). 
In agreement with the hypothesis that SAMHD1 restricts reverse transcription by 
regulating dNTP levels, Kim and colleagues observed that SAMHD1 expression strongly 
correlated with cellular dNTP concentrations in monocyte-derived macrophages 
(MDMs). Indeed, cell extracts from MDMs treated with Vpx containing VLPs, but not 
control VLPs, were able to facilitate an in vitro HIV RT-based primer extension assay 
(Kim et al., 2012). These observations are in agreement with early reports that the supply 
of exogenous dNTP to resting cell cultures was capable of overcoming their restriction to 
infection (Gao et al., 1993), (Amie et al., 2013a). 
SAMHD1 expression has been shown to correlate well with the permissiveness to 
infection by HIV (Laguette et al., 2011a). In addition to myeloid lineage cells, SAMHD1 
has recently been shown to mediate restriction of primary resting CD4+ T-cells (Baldauf 
et al., 2012). However, a number of nonrestrictive cell types including activated primary 
CD4+ T-cells and several cell lines including THP-1, 293FT, and HeLa are known to 
express measurable levels of SAMHD1. In addition, cycling U937 cells expressing 
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exogenous SAMHD1 were not restrictive to HIV infection. However, following 
differentiation to a noncycling state, following PMA treatment, both THP-1 and U937 
cells became restrictive to infection (White et al., 2013b). These observations indicated 
that SAMHD1 restriction may be regulated posttranslationally. To this end, several 
groups analyzed SAMHD1 for posttranslational modifications by mass spectrometry. 
Phosphorylation of T592 by Cdk1 was determined to negatively regulate SAMHD1 
restriction (White et al., 2013b; Cribier et al., 2013; Welbourn et al., 2013). Interestingly, 
while phosphorylation of T592 negatively affects SAMHD1 restrictive potential, no 
effect was observed on the triphosphohydrolase activity, indicating that enzymatic 
activity and restriction are separable characteristics of SAMHD1 (White et al., 2013b; 
Welbourn et al., 2013).  
 In addition to HIV, recent studies have also shown that SAMHD1 mediates 
restriction of a number of other viruses. SAMHD1 has been shown to restrict a number of 
other retroviruses (including FIV, BIV, EIAV, MLV, MPMV, and HTLV (White et al., 
2013a; Gramberg et al., 2013; Taya et al., 2014)), as well as several DNA viruses 
(Hollenbaugh et al., 2013; Kim et al., 2013). However, depletion of SAMHD1 by 
treatment with Vpx containing VLPs was not able to relieve restriction for all tested 
retroviruses (Gramberg et al., 2013). This is likely due in part to differential [dNTP] 
requirements of the reverse transcriptase enzyme of retroviruses (reviewed in (Amie et 
al., 2013a)). Additional aspects of SAMHD1 biology may play a role in the differential 
restriction of these and other viruses. For example, while the SAM domain is believed to 
be involved in regulating protein-protein interactions (Rice et al., 2009), it is dispensable 
for HIV restriction (White et al., 2013a); however, it is necessary for the control of the 
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endogenous LINE-1 retroelements (Zhao et al., 2013). 
 
 
Evolutionary Perspective on Vpr and Vpx Function 
Evolution of Vpr and Vpx 
 Recently, several groups have analyzed the evolutionary history of Vpr and Vpx. 
Until recently, the evolutionary origin of Vpx function remained contentious. While Vpr 
is common to all primate lentiviruses, SAMHD1 antagonism, and the Vpx gene itself, 
have been acquired and lost over the course of HIV/SIV evolution. By analyzing Vpx and 
Vpr proteins from a broad array of primate lentiviruses for the ability to degrade 
SAMHD1 and overlaying this functionality on a phylogenic tree of the Vpr/Vpx genes, 
Lim et al. demonstrated that SAMHD1 antagonism was acquired by an ancestral Vpr 
preceding the “birth” of Vpx. This neofunctionality appears to have occurred only once, 
at the most recent common ancestor of SIVagm and SIVmus/mon/gsn/syk (Lim et al., 
2011). Two key observations support this hypothesis: 1) the phylogenetically outgrouped 
SIVolc/wrc Vpr does not antagonize SAMHD1. 2) Vpr from SIVagm and 
SIVmus/mon/gsn/syk, which do not encode a Vpx gene, are able to facilitate SAMHD1 
degradation (Lim et al., 2011), as well as mediate G2 arrest (Planelles et al., 1996) 
(Figure 1.1). 
 Analysis of SAMHD1 evolution provides further support to the evolutionary 
history of Vpr and Vpx. By examining the ratio of nonsynonymous to synonymous 
substitution within the SAMHD1 gene across a broad array of primates, three groups 
were able to observe strong, episodic, positive selection of the SAMHD1 gene (Lim et 
al., 2011; Laguette et al., 2011b; Zhang et al., 2012). Both Lim and Laguette 
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demonstrated SAMHD1 to be under strong selective pressure in Old World (Catarrhines) 
but not New World (Platyrrhines) Monkeys (Laguette et al., 2011b; Lim et al., 2011). 
Notably, Lim et al. observed positive selection beginning at the ancestral node giving rise 
to the subfamily Cercopithecinae (which are infected with primate lentiviruses known to 
encode for SAMHD1 antagonism) but not subfamily Colobinae (infected by SIVolc/wrc) 
or Hominoids (infected by SIVcpz/gor/HIV-1)(Lim et al., 2011). In contrast, Laguette et 
al. observed positive selection of SAMHD1 beginning after the split of Old World 
Monkeys from New World Monkeys, earlier than that predicted by Lim et al. and 
continuing through Hominoid evolution (Laguette et al., 2012). These differences are 
most likely due to different primate samplings, as well as different computational 
modeling. Regardless, although the Laguette et al. model would point to an earlier onset 
of SAMHD1 antagonism, it still supports a model whereby SIV acquired this activity 
prior to the “birth” of Vpx. Surprisingly, all three groups observed strong positive 
selection of SAMHD1 along the Hominoid lineage of orangutans. As orangutans are not 
known to be infected by any lentiviruses, and no other retroviruses tested so far are 
known to antagonize SAMHD1, the causative agent of this selection is unclear.  
Interestingly, while HIV-1 and its zoonotic ancestor SIVcpz lack the ability to 
antagonize SAMHD1, the SIVs that gave rise to SIVcpz (SIVmus/mon/gsn and SIVrcm 
(Bailes et al., 2003)) both antagonize the SAMHD1 of their respective hosts, as well as 
human SAMHD1 in the case of SIVmus Vpr (Lim et al., 2011). Phylogenetic analysis 
indicates that SIVcpz lost SAMHD1 following recombination of SIVmus/mon/gsn and 
SIVrcm in which only the monofunctional SIVrcm Vpr was retained (Zhang et al., 2012; 
Etienne et al., 2013). This event was, at least in part, driven by the generation of a novel 
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Vif protein with enhanced hominid APOBEC3 antagonism (Etienne et al., 2013). It is 
tempting to speculate that the loss of SAMHD1 antagonism has, however, resulted in 
other profound changes in the pathology of lentiviral infection. For example, the reduced 
efficiency of myeloid cell infection by HIV-1 may result in reduced innate and 
subsequent adaptive immune activation, facilitating viral replication and pathogenesis. To 
this end, infection of myeloid cells by HIV-2 was recently shown to result in their 
activation through recognition of viral reverse transcripts by the cytosolic DNA sensor 
cyclic GMP-AMP synthase (cGAS); however, as HIV-1 is unable to complete reverse 
transcription, this activation was not observed (Lahaye et al., 2013; Puigdomenech et al., 
2012). Furthermore, infection of humans and mandrills by SAMHD1-antagonizing 
viruses has been observed to result in slower disease progression compared to infection 
with non-SAMHD1 antagonizing viruses (SIVmnd2 and HIV-2 vs SIVmnd1 and HIV-1) 
(Nyamweya et al., 2013; Souquière et al., 2009). Finally, a recently completed 20-year 
longitudinal study of HIV-1/HIV-2 dually infected individuals showed a delayed onset of 
AIDS in dually infected individuals, compared to HIV-1 only infected individuals. 
Furthermore, they observed individuals first infected by HIV-2 showed the longest time 
to onset of AIDS (Esbjörnsson et al., 2012). 
 
The Red Queen’s court 
 Antagonism of host restriction factors by pathogens is hypothesized to induce an 
evolutionary arms race, the Red Queen hypothesis, whereby host evolution away from 
antagonism results in a corresponding evolution by the pathogen to regain the ability to 
antagonize the restriction factor (reviewed in (Duggal and Emerman, 2012)). While 
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several studies have examined molecular determinants of Vpr and Vpx function, the 
evolutionary events leading to the “birth” of Vpx from a bifunctional Vpr, as proposed by 
Lim et al. (Lim et al., 2011), remain unclear. 
Following the identification of SAMHD1 as the Vpx-targeted myeloid restriction 
factor, several groups quickly demonstrated SAMHD1 was under strong evolutionary 
pressure (discussed above) (Lim et al., 2011; Laguette et al., 2011b; Zhang et al., 2012). 
The observation by Lim et al. that SAMHD1 is under positive selection in 
Cercopithecinae, but not New World Monkeys or Hominoids, strongly indicates that 
lentiviral infection has been the main driver of SAMHD1 evolution in primates. 
While Lim and Laguette both computationally identified residues under positive 
selection, those identified by Lim et al. were largely N-terminal, while those identified by 
Laguette et al. localized in the C-terminus (Lim et al., 2011; Laguette et al., 2011b). Both 
groups were able to molecularly verify the importance of these respective regions for 
Vpx antagonism; however, the apparent discrepancy between these two studies is likely 
due to different computational methodologies and Vpx-SAMHD1 species pairs 
molecularly tested. In agreement with Laguette, Ahn and colleagues were able to 
demonstrate that the C-terminus of human SAMHD1 was sufficient to mediate 
interaction with SIVmac Vpx (Ahn et al., 2012). However, a more thorough investigation 
by Fregoso et al. resolved the differences by generating a number of SAMHD1 chimeras, 
in which the N and C-termini of different species’ SAMHD1 were transposed, showing 
that the determinant of SAMHD1 interaction and degradation by Vpx has toggled back 
and forth between the N and C-terminus throughout the period of Vpx antagonism 
(Fregoso et al., 2013). 
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In contrast to the studies regarding Vpx-SAMHD1 co-evolution, little is currently 
known regarding the structural determinants of Vpr-mediated antagonism of the SLX4 
complex. Early studies demonstrated a species-specific ability of Vpr to induce G2 arrest 
(Planelles et al., 1996), indicative of positive selection on the Vpr-targeted factor. It is 
tempting to speculate that it became too difficult for Vpr to maintain concurrent 
evolutionary arms races with two host proteins. In support of this hypothesis, Spragg and 
Emerman recently examined the evolution of the biofunctional SIVagm Vpr and 
SAMHD1 from phenotypically and genetically distinct AGM species. While the four 
AGM species are only evolutionarily separated by 3 million years, each population is 
infected by distinct SIVagm. Even within this relatively short period of evolutionary 
time, Vpr from different SIVagm appear to utilize different interfaces for SAMHD1 
antagonism (Spragg and Emerman, 2013) .  
 
Molecular Insights into the Manipulation of the Cul4-DCAF1 Ligase  
by Vpr and Vpx 
Mechanisms of viral manipulation of ubiquitin ligases 
 Viral manipulation of the cellular ubiquitin ligase system is common across 
viruses from a diverse array of species (see Table 1.1). While the specific ligases 
manipulated and the restriction factors targeted are nearly as diverse as the viruses that 
manipulate them, three general strategies for altering the substrate specificity have been 
observed: 1) displacement of the substrate specificity receptor subunit of the ubiquitin 
ligase complex, as exemplified by the redirection of the Cul5-EloB/C complex towards 
APOBEC3 by Vif (Yu et al., 2003; 2004); 2) mimicry of endogenous substrate by a viral 
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protein, as seen in the case of Vpu manipulation of the Cul1-βTRCP (Margottin et al., 
1998); 3) generation of a new substrate interface, involving interaction of the new 
substrate with both the viral protein and the endogenous substrate receptor, as seen in the 
redirection of the Cul4-DCAF1 ligase towards SAMHD1 by Vpx (Schwefel et al., 2014) 
(Figure 1.2). In addition, there is at least one known virally encoded ubiquitin ligase, the 
ICP0 protein of herpes simplex viruses (Boutell et al., 2002)(field reviewed in (Barry and 
Früh, 2006)) 
 
Differential manipulation of DCAF1 substrate specificity by Vpr and Vpx 
 Alignment of Vpr and Vpx proteins gave early hints to the difference in substrate 
recruitment by the respective proteins. Structural studies of Vpr showed that it formed a 
tight 3 α-helix bundle flanked by unstructured N and C-termini (Morellet et al., 2003). 
Primary sequence alignment of the monofunctional HIV-1 Vpr, bifunctional SIVagm 
Vpr, and SIVmac Vpx show that this helical core is highly conserved among these 
proteins (Figure 1.3, grey boxes). DCAF1 binding was mapped to a short, highly 
conserved leucine-rich motif located in the third α-helix (Figure 1.3, red box) (Le Rouzic 
et al., 2007). Virion encapsidation of Vpr and Vpx was mapped independently to helix 2 
of the respective molecules (Yao et al., 1995; Mahalingam et al., 2001). These 
observations support the importance of this highly conserved helical core and its 
evolutionary conservation among primate lentiviral Vpr and Vpx.  
In contrast, a high degree of divergence is seen between the unstructured termini 
of Vpr and Vpx. Mutational analysis of Vpr identified the C-terminal region to be 
important for Vpr-mediated G2 arrest, and presumably SLX4 complex activation 
  
20 
(reviewed in (Morellet et al., 2009)). In support of this hypothesis, expression of Vpr 
S79A or Vpr R80A mutants or a Vpr 1-78 truncation acted in a dominant negative 
manner towards the induction of Vpr G2 arrest. Mutations to the N-terminal unstructured 
region of Vpr generally showed no effect on G2 arrest (reviewed in (Morellet et al., 
2009)); however, the homologous region within Vpx was shown to be necessary for Vpx 
to mediate myeloid cell infection  and SAMHD1 degradation (Gramberg et al., 2010; 
Ahn et al., 2012). Moreover, while substrate interaction of Vpr and Vpx appear to be 
heavily mediated by the C and N-terminus, respectively, several studies indicated these 
interactions are not defined by linear determinants. To this end, Maudet et al. examined 
Vpr for mutants that would fit 3 criteria: 1) inactive for G2 arrest induction, 2) retained 
DCAF1 binding, and 3) located outside the C-terminal tail. Two residues were identified 
matching these requirements, K27, located in the first α-helix, and Y50, located in the 
linker region between α-helix 2 and 3 (Maudet et al., 2011); however, the molecular 
mechanism by which these residues are involved in the induction of G2 arrest will need 
to be elucidated in light of the identification of the SLX4 complex as the Vpr target. 
Interestingly, the linker between the second and third α-helices was previously shown to 
be important for Vpr-UNG2 interaction (Figure 3, yellow box)(Selig et al., 1997). In 
addition, the linker between the second and third α-helix of Vpx was recently shown to 
be involved in the Vpx-SAMHD1 interaction (Figure 3, orange boxes)(Schwefel et al., 
2014).  
Until recently, the exact mechanism by which Vpr and Vpx altered the substrate 
specificity of the Cul4-DCAF1 ubiquitin ligase remained unclear. Direct interaction 
between Vpr/Vpx and the substrate specificity subunit, DCAF1, of the ubiquitin ligase is 
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reminiscent of the endogenous substrate mimicry mechanism observed in the case of 
Vpu-mediated degradation of CD4 and Tetherin (Figure 1.2) (Margottin et al., 1998). 
DCAF1 is a large, 1507 amino acid, multiple domain protein comprised of a N-terminal 
armadillo domain (unknown function), a central LisH domain (involved in the 
dimerization of DCAF1 containing ubiquitin ligases (Ahn et al., 2011)), a WD40 domain 
(common to all DCAFs (Jin et al., 2006), involved in mediating substrate interaction), 
and a C-terminal acidic amino acid rich region (involved in the regulation of DCAF1 
activity (Li et al., 2010))(reviewed in (Nakagawa et al., 2013)). 
In agreement with the hypothesis that Vpr altered the specificity of DCAF1 by 
mimicking endogenous substrate, Le Rouzic et al. demonstrated that Vpr interacted 
directly with the DCAF1 WD40 domain. This interaction was shown to be mediated by 
the leucine rich motif within the third α-helix of Vpr (Figure 1.3, red box) (Le Rouzic et 
al., 2007). The high conservation of this motif in Vpx, as well as in the predicted tertiary 
structure of Vpr and Vpx supported the hypothesis that Vpr and Vpx altered DCAF1 
specificity in a similar manner (reviewed in (Dehart and Planelles, 2008)). 
Through identification of endogenous substrates and inhibitors of DCAF1, 
functional roles of several DCAF1 subdomains have been elucidated. However, direct 
interaction of Vpr and Vpx with the DCAF1 WD40 domain (Le Rouzic et al., 2007; 
Schwefel et al., 2014) has raised the question as to whether DCAF1 merely serves as a 
bridge linking Vpr and/or Vpx to the ubiquitin ligase complex to facilitate substrate 
degradation. Gerard et al. recently demonstrated that expression of the truncation 
minimally able to bind DDB1 (WD40 domain, plus a short region N-terminal to the 
WD40 domain known to mediate DCAF-DDB1 interaction (Li et al., 2009)) was unable 
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to facilitate induction of G2 arrest by Vpr in DCAF1-depleted cells (Gérard et al., 2014). 
In agreement with this observation, we have observed that truncation of any DCAF1 
domain inhibits both Vpr and Vpx function in a dominant negative manner, indicating 
that DCAF1 does not merely serve as a bridge linking Vpr/Vpx to the Cul4 ligase (see 
Chapter 1). 
In 2014, Schwefel et al. solved the crystal structure of a complex involving the 
DCAF1 (WD40 domain), SIVsm Vpx, and the SAMHD1 (C-terminal domain)(Schwefel 
et al., 2014). Similar to the interaction seen between other DCAFs and their substrates 
(Song and Kingston, 2008; Patel et al., 2008)(Reviewed in (Stirnimann et al., 2010)), 
Vpx was observed to interact with the DCAF1-WD40 domain primarily through 
interactions with a shallow groove on the top face of the WD40 domain. In agreement 
with previous observations that mutations to Vpx Q76 abrogate binding to DCAF1 
(Srivastava et al., 2008), this residue was shown to hydrogen bond with DCAF1 N1135 
and W1156. In addition to their role in coordinating Vpx Q76, DCAF1 N1135 and 
W1156 are involved in interactions with a number of residues in the first α-helix of Vpx 
(Schwefel et al., 2014). Through a mutagenic screen of DCAF1, we independently 
identified these residues as being involved in the Vpx interaction, as their mutation 
results in an inability of mutant (N1135A or W1156H) DCAF1 to co-immunoprecipitate 
Vpx (see Chapter 1). Additionally, both DCAF1 mutants acted in a trans dominant 
negative manner in regard to Vpx-mediated SAMHD1 degradation. While Vpr and Vpx 
share high homology in both the first and third α-helix, both DCAF1 N1135A and 
W1156H retain interaction with Vpr. Functional competition assays show Vpr is able to 
inhibit Vpx-mediated SAMHD1 degradation, while the reciprocal is not observed (see 
  
23 
Chapter 1). Two, nonmutually exclusive, models could explain the difference observed 
by us in regards to the interaction of DCAF1 with Vpr and Vpx, respectively: 1) higher 
affinity interaction between Vpr and DCAF1, than Vpx and DCAF1; 2) differential 
binding conformations of the Vpr-DCAF1 complex vs. Vpx-DCAF1 complex. Further 
biochemical studies will be necessary to fully distinguish between these two models.  
Perhaps the most surprising observation from the Schwefel and colleagues 
structure is that SAMHD1 recruitment to the Vpx-DCAF1 complex involves direct 
interaction of SAMHD1 with DCAF1. This observation is in contrast to previous models 
of UPS manipulation by viral proteins in which restriction factor recruitment was 
dependent on interaction only with the viral protein (reviewed in (Barry and Früh, 2006)). 
In agreement with Schwefel et al., we observed that mutation of the DCAF1 residue 
D1092 inhibited Vpx-mediated SAMHD1 degradation in a dominant negative manner, 
but does not disrupt the Vpx-DCAF1 interaction (see Chapter 1). In further support of the 
differential modulation of DCAF1 specificity by Vpr and Vpx, while Vpx has been 
shown to interact with SAMHD1 independent of DCAF1 binding (Laguette et al., 
2011a), Vpr Q65R (which is unable to bind DCAF1) did not co-immunoprecipitate with 
members of the recently described G2 arrest target (SLX4 or Mus81)(Laguette et al., 
2014), supporting a model in which Vpr and Vpx modulate DCAF1 specificity by 
different mechanisms. Indeed, current studies show Vpr modulates the activity of DCAF1 
towards endogenous substrates (Wen et al., 2012; Laguette et al., 2014). However, it 
remains unclear if this is a general function of Vpr manipulation of DCAF1, increasing 
the ubiquitination of all endogenous DCAF1 targets, or a more specific redirection of 
DCAF1 towards a limited subset of endogenous substrates. In contrast, Vpx appears to 
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exclude interaction of DCAF1 with at least some endogenous substrates, UNG2 and 
SLX4 complex (Laguette et al., 2014). 
  
Consequences of lentiviral manipulation of the Cul4-DCAF1  
ubiquitin ligase 
 Several studies have made intriguing observations regarding the broader effects of 
Vpr manipulation of the Cul4-DCAF1 ubiquitin ligase. Cullin-based ubiquitin ligase 
activity is dependent on auto-conjugation of a ubiquitin like modifier, NEDD8, to the 
Cullin backbone, resulting in conformational changes which facilitate E2 recruitment and 
ubiquitin transfer to substrate (Saha and Deshaies, 2008; Duda et al., 2008)(reviewed in 
(Soucy et al., 2010; Saifee and Zheng, 2008)). Intriguingly, Hrecka observed that Vpr 
preferentially associates with neddylated Cul4 (Hrecka et al., 2007). While the regulation 
of Cullin neddylation is still not fully understood, recruitment of substrate-bound receptor 
has been shown to, at least in part, promote conjugation of NEDD8 to Cullins (Chew and 
Hagen, 2007). These observations promote the hypothesis that Vpr binding of DCAF1 
may drive assembly of active Cul4-DCAF1 complexes. Several additional lines of 
evidence support this hypothesis. Namely, other viral proteins are known to manipulate 
Cul4 ubiquitin ligase specificity by binding directly to DDB1 (see Table 1.1), resulting in 
the exclusion of DCAFs (Angers et al., 2006). We have observed that Vpr expression 
decreases the ability of one such viral protein, SV5 V-protein, to exclude DCAF1 from 
binding DDB1 (unpublished results). Furthermore, Vpr expression promotes the 
exclusion of other DCAFs (Schröfelbauer et al., 2007). Whether Vpx induces similar 
changes will require further investigation. However, preliminary evidence suggests at 
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least some differences between Vpr and Vpx in regards to Cul4 complex assembly. While 
Vpr has been observed to in result in an increased association of DCAF1 with DDB1, 
Vpx expression does not alter the DCAF1-DDB1 interaction (see Chapter 2). 
 The broader implications of viral manipulation of ubiquitin ligases have remained 
largely unstudied. Most studies into the manipulation of ubiquitin ligases by viral 
proteins have focused on the mechanism by which they interact with and redirect the 
specificity of their partner ligases. How these subversions alter the activity of these 
ligases towards their endogenous targets has been largely ignored. One recent study 
points to large alterations in the activity of the cellular ubiquitin ligase system by Vpr, but 
not other HIV-1 accessory proteins (Arora et al., 2014); however, the implications of this 









Table 1.1: Viral manipulators of the cellular ubiquitin proteasome system 
Virus Viral Protein 
UPS 
Interaction Target Function Reference 
HPV E6 HECT/E6-AP p53 Dysregulation of cell cycle 
(Scheffner et al., 
1993) 
Paramyxovirus  
SV5 V Cullin4/DDB1 STAT1,2 
Overcome type-1 
interferon responses (Horvath, 2004) 
Hepatitis B HBx Cullin4/DDB1 Unknown 
Apoptosis, DNA 
repair, 
cell cycle, and 
enhanced viral 
replication 
(Sitterlin et al., 2000; 
Leupin et al., 2005) 
 
Vpu Cullin1/β-TrCP1 CD4, Tetherin 
 
Enhance viral release 
 
(Bour et al., 2001; 
Margottin et al., 1998) 
HIV-1 Vif Cullin5/EloginB/C APOBEC3G/F Overcome restriction 
(Yu et al., 2003; 
Mehle et al., 2004; 
Sheehy et al., 2003) 
 
 
Vpr Cullin4/DDB1-DCAF1 SLX4 complex 
Prevent recognition of 
viral reverse 
transcripts by DNA 
sensors 
(Dehart et al., 2007; 
Le Rouzic et al., 
2007; Schröfelbauer 
et al., 2007; Hrecka et 
al., 2007; Belzile et 
al., 2007; Wen et al., 
2007) 





(Srivastava et al., 
2008; Hrecka et al., 
2011; Laguette et al., 
2011a) 
HCMV UL35 Cullin4/DDB1-DCAF1 Unknown 
Induce ATR-
dependent  
cell cycle arrest 
in G2 
(Salsman et al., 
2012) 
Herpes 
 Viruses ICP0 RING Finger E3 PML 
Overcome antiviral 
activity associated 
with PML nuclear 
bodies 
(Boutell et al., 2002) 




Prevent recognition of 
viral DNA ends by the 
NHEJ machinery 
(Harada et al., 


















Figure 1.1: Overview of Vpr/Vpx phylogeny  
Branch lengths are not depicted to scale. Adapted from (Lim et al., 2011; Laguette et al., 
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Figure 1.2: Mechanisms of viral manipulation of cellular ubiquitin ligases 
Three mechanisms of viral manipulation of the UPS have been observed. 1) Through the 
displacement of the substrate specificity subunit of the ubiquitin ligase, the viral protein 
is able to recruit nonnative substrate. This mechanism is exemplified by the primate 
lentiviral proteins Vif manipulation of the Cul5 ubiquitin ligase. Vif has been shown to 
displace the native ligase receptor family, SOCS, through direct interaction with Cul5, as 
well as interactions with the adaptor proteins EloB/C (Yu et al., 2003; 2004). 2) Viral 
mimicry of endogenous ubiquitin ligase substrate. Cul1-SKP1-βTRCP is known to recruit 
substrates through interaction with a phospho-degron. Vpu is known to be 
phosphorylated on S52 and S56, generating a βTRCP phospho-degron motif. This 
substrate mimicry by Vpu facilitates the recruit by it of CD4 and Tetherin to the Cul1 
ubiquitin ligase for ubiquitination and degradation (Margottin et al., 1998). 3) Generation 
of a novel substrate binding interface as recently described by Schwefel et al. Vpx was 
shown to interact with DCAF1, the substrate specificity subunit of the Cul4 ubiquitin 
ligase (Le Rouzic and Benichou, 2005; Srivastava et al., 2008), this binding results in the 
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 CHAPTER 2  
 
UNDERSTANDING THE MOLECULAR MANIPULATION OF THE CUL4-DDB1-
DCAF1 UBIQUITIN LIGASE BY THE PARALOGOUS LENTIVRIAL  
ACCESSORY PROTEINS VPR AND VPX 
 
Abstract 
 The primate lentiviral proteins Vpr and Vpx are both known to manipulate the 
cellular ubiquitin ligase comprised of Cul4-DDB1-DCAF1 to facilitate viral replication. 
While Vpr is common to all primate lentiviruses, Vpx is encoded only by a limited range 
of SIVs and HIV-2. Although Vpr and Vpx share a high degree of homology, they are 
known to mediate markedly different benefits for viral replication through the 
recruitment of different substrates to the ubiquitin ligase. Here we explore the interaction 
of Vpr and Vpx with the ubiquitin ligase substrate specificity receptor DCAF1. Through 
mutational analysis of DCAF1, we demonstrate that although Vpr and Vpx share a highly 
similar DCAF1 binding motif, they interact with DCAF1 differently. In addition, we 







Manipulation of the cellular ubiquitin proteasome system (UPS) to degrade 
cellular restriction factors is a common tactic employed across a broad array of virus 
classes. Human Immunodeficiency Virus (HIV) is no exception and encodes three such 
proteins (Vif, Vpu, and Vpr). In addition, some primate lentiviruses (including HIV-2) 
encode the Vpr paralog Vpx. While the mechanism of UPS manipulation and cellular 
targets of Vif and Vpu have been well characterized, the functions of Vpr and Vpx have 
been more difficult to elucidate (reviewed in (Malim and Emerman, 2008)). 
 Vpr is a short, 96aa protein that is highly conserved among primate lentiviruses 
(HIVs and SIVs). Vpr is expressed late during viral replication and is present in virions; 
however, its role within the virion is unknown (Cohen et al., 1990; Müller et al., 2000). 
Its function appears to be highly crucial for HIV infection as no primary isolates have 
been described which lack Vpr (reviewed in (Andersen et al., 2008)). Vpr has been 
shown to induced cell-cycle arrest at the G2/M transition through the activation of the 
DNA damage sensor ataxia telangiectasia and Rad3-related protein (ATR) (Roshal et al., 
2003); however, the significance of cell cycle arrest for the virus is currently unclear 
(reviewed in (Andersen et al., 2008)). 
 In 1994, Vpr was shown to interact with a novel cellular protein, DDB1-Cullin4 
Associated Factor 1 (DCAF1), previous known as RIP/VprBP (Zhao et al., 1994). The 
significance of this interaction remained unclear until several groups identified DCAF1 
as a substrate specificity subunit for the Cullin4-DDB1-based ubiquitin ligase. Following 
this observation, our laboratory and several others proposed a model whereby Vpr hijacks 
the cellular ubiquitin ligase composed of Cullin4-DDB1-DCAF1 (hereafter referred to as 
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Cul4-DCAF1) recruiting an as of yet unidentified cellular target, resulting in its 
polyubiquitination and degradation (Dehart et al., 2007; Le Rouzic et al., 2007; 
Schröfelbauer et al., 2007; Hrecka et al., 2007; Belzile et al., 2007; Wen et al., 2007). 
 In addition to Vpr, some primate lentiviral lineages encode the Vpr paralog Vpx. 
Early studies identified a role for Vpx in the infection of myeloid lineage cells, dendritic 
cells, and macrophages, by overcoming a block present in these cells to viral reverse 
transcription (Yu et al., 1991). Following studies demonstrating that Vpr manipulated 
Cul4-DCAF1, the Skowronski lab demonstrated a similar requirement for Vpx to 
facilitate macrophage infection (Srivastava et al., 2008). In 2011, two groups identified 
SAMHD1 as the cellular protein targeted by Vpx, in the context of Cul4-DCAF1 
(Laguette et al., 2012; Hrecka et al., 2011). 
 While much work has been done to understand the functional role of Vpr and Vpx 
in the context of viral replication, the mechanism by which they redirect the specificity of 
Cul4-DCAF1 has remained unresolved. Thus far, three mechanisms for manipulation of 
proteasomal degradation of cellular proteins have been observed: 1) the encoding of a 
viral E3 ubiquitin ligase, as is the case of the ICP0 protein of herpes viruses (Boutell et 
al., 2002), 2) the replacement of the substrate receptor of a cellular ubiquitin ligase by a 
virally encoded protein, as is the case of protein V from SV5 (Horvath, 2004) and Vif of 
primate lentiviruses (Yu et al., 2003; Mehle et al., 2004; Sheehy et al., 2003), and 3) 
mimicry of endogenous substrate by the viral protein, which ferries a cellular protein to 
be targeted for ubiquitination, as observed in the manipulation of Cul1-βTRCP by HIV-1 
Vpu (Bour et al., 2001; Margottin et al., 1998).  
 In this study, we aim to investigate the manner by which Vpr and Vpx interact 
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with DCAF1, resulting in an alteration of substrate specificity. Using mutational analysis 
of the DCAF1 substrate-binding interface, we propose that although Vpr and Vpx share a 
highly homologous DCAF1 binding motif, Vpr and Vpx interact with the Cul4-DCAF1 
ubiquitin ligase differently. In addition, we observe that Vpr and Vpx functions are 
dependent on DCAF1 WD40 domain residues not directly involved in binding Vpr or 
Vpx. Based on these observations and other recently published results, we propose a 
model whereby Vpr and Vpx recruit substrate in an unusual manner involving direct 
interaction between the virally defined substrate and DCAF1. 
 
 
Materials and Methods 
Cell culture 
Exponentially growing 293FT and HeLa cells were cultured in Dulbecco minimal 
essential medium (DMEM)(Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) and 1% L-glutamine (Invritogen). 293FT cells were transfected 
using the Calcium Phosphate method, as previously described (Zhu et al., 2001). 36 hr 
posttransfection cells were harvested, washed 2x with Phosphate Buffered Saline (PBS), 
and lysed as described below. HeLa cells were transfected with the FuGene HD 
(Promega, Madison, WI) per manufacturer’s protocol.  
 
Plasmids 
Flag-DCAF1 was purchased from GeneCopeia (Germantown MD). DCAF1 
truncations were made by generating unique restrictions sites where indicated (Figure 
2.1) using Quikchange Lightning site-direct mutagenesis (Agilent Technologies, Santa 
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Clara, CA) per manufacturer’s recommendations. DCAF1 WD40 point mutants were 
generated by site-generated mutagenesis using Quikchange Lightning according to 
manufacturer’s recommendation. Primers were designed utilizing Agilent Technologies 
Quikchange online primer design tool. Myc-huSAMHD1 was purchase from OriGene 
(Rockville, MD). pcDNA3.1 was purchased from Invitrogen. HA-Vpr and HA-Vpx were 
subcloned from pHR-HA-Vpr/Vpx-ires-GFP (Dehart et al., 2007) into pFIN-EF1-GFP-
2a-mCherH-WPRE (a kind gift of Dr. Semple-Rowland)(Verrier et al., 2011) in the place 
of mCherH. 
 
Immunoprecipatations and Western blots 
For immunoprecipation, cells were gentle detached by incubation in PBS and 
pelleted at 13,000rpm for 5 min in a tabletop microcentrifuge. Cells were lysed with Flag 
IP buffer (50 mM Tris HCI, pH 7.4, 15 0mM NaCl, 1 mM EDTA, and 1% TRITON X-
100) in the presence of protease inhibitors (Complete EDTA free tablets; Roche, 
Indianapolis, IN). Lysate protein concentrations were determined by Pierce™ BCA 
(Thermo Scientific, Rockford, IL) and brought to equal protein concentration. Lysates 
were subject to immunoprecipitation using Anti-FLAG® M2 Magnetic Beads (SIGMA-
ALDRICH, St. Louis, MO) in accordance with manufacturer recommendations. Briefly, 
lysates were incubated with beads for 2 hr (at RT) to overnight (at 4ºC). Beads were 
washed 5x with lysis buffer and proteins eluted with 3x-FLAG® Peptide, 100 µg/ml for 1 
hr at RT. Cells used in degradations assays were lysed in SET Buffer (1% SDS, 50 mM 
Tris HCL, pH 7.4, 1 mM EDTA); lysates were thoroughly denatured by boiling for 5 
min. Lysates and immunoprecipation samples were resolved by SDS-PAGE on 4-10% 
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Criteron™ TGX™ gels (Bio Rad, Hercules, CA) per manufacturer’s recommendations 
and transferred to PVDF membrane (EMD Millipore, Billerica, MA). The following 
antibodies were used: FLAG® M2 and β-actin (Sigma Aldrich), HA.11 and 9E11(c-
Myc)(Covance), DDB1 (Abcam). 
 
Lentiviral vectors 
pHR-Vpr-IRES-GFP, pHR-Vpr(R80A)-IRES-GFP, pHR-Vpx293-IRES-GFP, 
and pHR-GFP viruses were produced as previously described (Zimmerman et al., 2004; 
Roshal et al., 2003). Briefly, 293FT cells were transfected as described earlier with 
transfer vector, pCMV ∆8.2∆Vpr packaging plasmid, and pCMV-VSVG envelope 
plasmid at a ratio of 2.5:2.5:1. Supernatants were collected every 24 hr, until the cell 
monolayer died, and cleared of cell debris by centrifugation at ~825x-g for 5 min. Pooled 
supernatant was concentrated by ultracentrifugation at 25,000x-g for 2 hr. Concentrated 
virus was resuspended in DMEM with 10% FBS and 1% L-Glutamine and stored at -
80ºC. HeLa cells were transduced in in presence of 10 µg/ml polybrene overnight. Viral 
titers were determined by GFP expression.  
 
FACS and cell cycle analysis 
HeLa cells were detached by trypsinization and washed in fluorescence-activated 
cell sorting (FACS) buffer (2% FBS and 0.02% Sodium Azide in PBS). For analysis of 
GFP, cells were immediately subject to flow cytometry. Cells for cell cycle analysis were 
pelleted at ~825x-g for 5 min and fixed with 70% ethanol at -20ºC overnight. Fixed cells 
were rehydrated by 2x wash in PBS. DNA content was determined by staining in 50 
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µg/ml propidium iodide in 0.1% Triton X-100 PBS with RNase A for 20 min. Cells were 
analyzed on a BD FACS Canto II flow cytometer using the FACSDiva software (Becton 




DCAF1 interacts with the Cul4-DDB1 ubiquitin ligase backbone  
through a motif N-terminal to the WD40 domain 
 The modular nature of many cellular ubiquitin ligases allows for the regulated 
targeting and degradation of a diverse array of substrates (Nalepa et al., 2006). In the case 
of the Cul4-based ligases, the core ubiquitin ligase comprised of Cul4-Rbx1-DDB1 has 
been shown to interact with a large number of substrate receptors termed DDB1-Cullin4 
Associated Factors (DCAFs) (Angers et al., 2006; He et al., 2006; Higa et al., 2006; Jin et 
al., 2006). In 2007, our group and several others demonstrated that the HIV accessory 
protein Vpr interacted directly with DCAF1, resulting in a robust cell cycle arrest at the 
G2/M transition (Dehart et al., 2007; Le Rouzic et al., 2007; Schröfelbauer et al., 2007; 
Hrecka et al., 2007; Belzile et al., 2007; Wen et al., 2007). Subsequently, it was shown 
that the HIV-2/SIVagm Vpr paralog Vpx also utilized the same ubiquitin ligase 
(Srivastava et al., 2008). 
Molecular analyses of DCAFs have revealed that most consist primarily of a 
WD40 domain (Higa et al., 2006), a highly conserved β-propeller structure involved in 
mediating protein-protein interactions (Stirnimann et al., 2010). In contrast, the complex 
domain architecture of DCAF1 (comprised of an N-terminal armadillo domain, a central 
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LisH domain, a C-terminal WD40 domain, and a highly acidic C-terminal tail) makes it 
unique among DCAFs (Jin et al., 2006) (Figure 2.1). In order to better determine the 
manner in which Vpr and Vpx manipulate the Cul4-DCAF1 ubiquitin ligase, we 
generated a number of Flag-tagged DCAF1 truncation mutants in which each domain has 
been removed individually or in conjunction with others. In addition, the annotated but 
undescribed DCAF1 isoform 3, which contains a large truncation in the armadillo domain 
generated via alternative splicing, was also tested (Figure 2.1). The ability of these Flag-
DCAF1 truncations to interact with Vpr/Vpx and the Cul4-DDB1 ligase backbone was 
analyzed by co-immunoprecipitation (Co-IP). 
Interaction of Vpr/Vpx with DCAF1 alone would not be expected to facilitate 
their function as ubiquitination of cellular proteins by DCAF1 requires interaction with 
the Cul4-DDB1 ubiquitin ligase backbone. To this end, Flag-DCAF1 truncations were 
analyzed for the presence of DDB1. As expected, full length DCAF1, both isoform 1 and 
isoform 3, were capable of interacting with DDB1 (Figure 2.2, lanes 2 and 3). In 
agreement with previous observations indicating a role of the WD40 domain in DDB1 
interaction (Angers et al., 2006), truncations lacking the WD40 domain lost the ability to 
interact with DDB1 (Figure 2.2, lanes 4, 6-8). Surprisingly, the Flag-DCAF1 WD40 was 
unable to immunoprecipitate DDB1 (Figure 2.2, lane 11). This is in contrast to earlier 
reports in which “WD40” truncations were able to interact with DDB1 (Gérard et al., 
2014; Le Rouzic et al., 2007). Most likely, this discrepancy is due to differences in 
truncation length (residues 1041-1377(Le Rouzic et al., 2007), 1041-1393(Gérard et al., 
2014), and 1073-1396 in this manuscript). Recently, it was demonstrated that interaction 
between DCAFs and DDB1 is facilitated by a cryptic α-helix located N-terminal to the 
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WD40 domain (termed an Hbox) (Li et al., 2009). Gérard et al. recently determined the 
putative DCAF1 Hbox spans 1049-1062, which is absent from our WD40 truncation. In 
agreement with this hypothesis, the minimal truncation we generated of DCAF1 capable 
of interacting with DDB1 was that containing the LisH and WD40 domains (Figure 2.2, 
lane 9). As expected, truncations lacking this region were unable to interact with DDB1. 
Interestingly, the ∆acidic truncation lost the ability to interact with DDB1 (Figure 2.2, 
lane 5). It has recently been shown that the acidic C-terminal tail is involved in regulatory 
function via interaction with the protein Merlin (Li et al., 2010). It is tempting to 
speculate that loss of DDB1 interaction by this truncation is due to regulatory activities 
mediated by the acidic tail. 
 
Mutations of DCAF1 WD40 substrate binding interface disrupt  
Vpx-mediated SAMHD1 degradation 
 In order to determine the molecular mechanism by which the paralogous lentiviral 
accessory proteins Vpr and Vpx manipulate the substrate specificity of DCAF1, we 
generated a number of point mutations to the WD40 domain of DCAF1 (Table 2.1). 
Substrate interaction by DCAFs is believed to be mediated by interaction with this β-
propeller structure. Previous reports have demonstrated that the “top” (by convention) of 
WD40 domains form a shallow groove that mediates interaction with proteins to be 
targeted for degradation (reviewed in (Trievel and Shilatifard, 2009; Stirnimann et al., 
2010)). Using homology modeling between DCAF1 and the most closely related DCAF 
(WDR5) with a known structure (Figure 2.3A)(Schuetz et al., 2006; Song and Kingston, 
2008; Patel et al., 2008), as well an in silico (ModBase) structural prediction of DCAF1’s 
WD40 domain (Pieper et al., 2014)(Figure 2.3B), we generated a series of point 
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mutations which we predicted would fall around this substrate binding region.  
293FT cells were transfected with DCAF1 truncations and point mutants,  
HA-Vpx and Myc-SAMHD1, and screened for the inhibition of Vpx-mediated 
degradation of SAMHD1, its recently described target (Laguette et al., 2011; Hrecka et 
al., 2011). Interestingly, DCAF1 truncations fail to mediate SAMHD1 degradation by 
Vpx (data not shown, and Figure 2.4). Specifically, the minimal truncation generated 
capable of binding DDB1, DCAF1 LisH-WD40, no longer mediated SAMHD1 
degradation, indicating that binding of Vpx to the Cul4 ubiquitin ligase is not sufficient to 
mediate its activity. This observation indicates DCAF1 does not merely serve as a bridge 
by which Vpx brings SAMHD1 to the Cul4 ubiquitin ligase. In addition, several point 
mutants (D1092A, N1135A, and W1156H) were identified that failed to facilitate the 
degradation of SAMHD1 by Vpx (Figure 2.4, lanes 10, 12-13). Analysis of additional 
residues (H1134A and D1256A) to DCAF1 WD40 domain (Figure 2.4, lanes 11 and 14) 
as well as others (data summarized in Table 2.1) show no effect on the SAMHD1 
degradation activity of Vpx, indicating that mutations to this region do not generally 
perturb Vpx function. 
 
DCAF1 WD40 mutations disrupt Vpx binding 
 In order to better understand how these DCAF1 mutations disrupt Vpx function, 
they were analyzed for their ability to interact with Vpx by co-IP. As expected, 
immunoprecipitation of full length Flag-DCAF1 was able to bring down Vpx (Figure 2.5, 
lane 4). Interestingly, in contrast to previous reports regarding the highly related lentiviral 
protein Vpr ((Le Rouzic et al., 2007) and this report), the WD40 domain of DCAF1 was 
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not sufficient to co-IP Vpx (Figure 2.5, lane 5), while the longer truncation containing 
both the LisH and WD40 domains regained this function (Figure 2.5, lane 6), indicating 
that Vpx-DCAF1 interaction may involve residues outside of the WD40 region or may be 
dependent on assembly of the complete ubiquitin ligase machinery. Co-IP analysis of 
DCAF1 WD40 mutants revealed Vpx-mediated SAMHD1 degradation can be inhibited 
without disrupting Vpx binding. While DCAF1 mutations D1092A, N1135A, and 
W1156H all disrupted Vpx-mediated SAMHD1 degradation, only N1135A and W1156H 
(Figure 2.5, lanes 9 and 10) result in a loss of Vpx interaction, explaining their inability 
to mediate SAMHD1 degradation. 
Interestingly, DCAF1 D1092A, which failed to facilitate SAMHD1 degradation, 
retained binding to Vpx (Figure 2.5, lane 7). Based on these results and a recently 
published co-crystal of DCAF1 (WD40, residues 1058-1296)-Vpx-SAMHD1 (C-term) 
(Schwefel et al., 2014) we propose a novel mechanism by which Vpx alters the substrate 
specificity of the DCAF1-containing ubiquitin ligase. In this model, Vpx generates a 
novel substrate binding surface involving Vpx and DCAF1 in the recruitment of 
SAMHD1. 
Co-IP analysis of DCAF1 WD40 mutants revealed Vpx-mediated SAMHD1 
degradation can be inhibited without disrupting Vpx binding. While DCAF1 mutations 
D1092A, N1135A, and W1156H all disrupted Vpx-mediated SAMHD1 degradation, 
only N1135A and W1156H (Figure 2.5, lanes 9 and 10) result in a loss of Vpx 
interaction, explaining their inability to mediate SAMHD1 degradation. Interestingly 
DCAF1 D1092A, which failed to facilitate SAMHD1 degradation, retained binding to 
Vpx (Figure 2.5, lane 7). Based on these results and a recently published co-crystal of 
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DCAF1(WD40, residues 1058-1296)-Vpx-SAMHD(C-term) (Schwefel et al., 2014), we 
propose a novel mechanism by which Vpx alters the substrate specificity of the DCAF1- 
containing ubiquitin ligase. In this model, Vpx generates a novel substrate binding 
surface involving Vpx and DCAF1 in the recruitment of SAMHD1. 
 
Vpr interacts with DCAF1 differently than Vpx 
 While a recently published crystallographic study determined the Vpx-DCAF1 
binding interface, no structural data exist regarding the Vpr-DCAF1 interaction 
(Schwefel et al., 2014). A high degree of homology between Vpr and Vpx led us to 
hypothesize they would interact with DCAF1 in a similar manner. Analogous mutations 
in the third helix of both Vpr (Q65R) and Vpx (Q76R) have been shown to abrogate their 
ability to interact with DCAF1 (Dehart et al., 2007; Le Rouzic et al., 2007; Schröfelbauer 
et al., 2007; Belzile et al., 2007; Srivastava et al., 2008). However, several studies point 
towards different mechanisms of DCAF1 manipulation by Vpr and Vpx. Most striking 
perhaps are the observations regarding interaction of Vpr and Vpx with their respective 
targets. While Vpx and SAMHD1 have been observed to form stable binary complexes 
independent of DCAF1 (Hrecka et al., 2011), Vpr mutants unable to bind DCAF1 were 
not able to interact with the newly identified G2 arrest target(s), SLX4 and Mus81 
(Laguette et al., 2014). 
In order to examine the molecular interaction between DCAF1 and Vpr, DCAF1 
mutations were tested for their ability to interact with Vpr. As expected, Vpr was able to 
co-IP with Flag-DCAF1 (Figure 2.4, lane 4). In agreement with previously published 
observations (Le Rouzic et al., 2007), the DCAF1 WD40 domain was sufficient to 
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mediate Vpr binding (Figure 2.6, lane 5). The longer LisH-WD40 truncation also retained 
Vpr binding (Figure 2.6, lane 6). In contrast to Vpx, both the N1135A and W1156H 
mutants retained Vpr binding (Figure 2.6, lanes 9 and 10).  
Recently, several groups demonstrated Vpr alters Cul4-DCAF1 function by 
enhancing ubiquitination of specific endogenous targets, UNG2 and SLX4 complex 
(Wen et al., 2012; Laguette et al., 2014), raising the possibility that mutations to DCAF1 
WD40 may inhibit Vpr-mediated G2 arrest without abrogating Vpr binding. In order to 
assess the effect of DCAF1 truncations and WD40 mutants on Vpr-mediated G2 arrest, 
HeLa cells were transfect with Vpr in the presence or absence of DCAF1 mutants. 36 hr 
posttransfection cells were harvested and analyzed for G2 arrest by FACS. As expected, 
G2 arrest was observed in cells transfected with Vpr alone or with WT DCAF1. 
Expression of either DCAF1 WD40 or LisH-WD40 was observed to inhibit Vpr-
mediated G2 arrest in a dominant negative manner (Figure 2.7). One possible explanation 
for this effect is that these truncations may serve as molecular sinks for Vpr (capable of 
binding Vpr or Vpr and DDB1, respectively, but not the G2 substrate) reminiscent of the 
previously described effect of DDB1 overexpression (Wen et al., 2007). Surprisingly, 
several DCAF1 WD40 mutants (D1092A, N1135A, W1156H, and D1256A) also 
inhibited the induction of G2 arrest by Vpr. These observations demonstrate Vpr activity 
is more sensitive to DCAF1 WD40 mutations than Vpx. 
 
Vpr Function is dominant to Vpx 
 Discrepancies with regard to DCAF1-mutant binding to Vpr and Vpx may be 
explained by two, nonmutually exclusive, hypotheses: 1) differential binding affinities of 
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Vpr and Vpx to DCAF1 and/or 2) differential binding interfaces in the Vpr-DCAF1 vs 
Vpx-DCAF1 interaction. In order to distinguish between these to hypotheses, we 
examined the functional competition between Vpr and Vpx. To this end, HeLa cells were 
transduced with virus expressing Vpr and either a control virus (GFP), Vpx, or the 
dominant negative Vpr mutant R80A (Dehart et al., 2007). 36 hr posttransduction cell 
cycle profiles were determined for each cell population. As expected, Vpr transduced 
cells arrested in G2 (Figure 2.8). Co-expression of Vpr R80A reduces the percentage of 
cells in the G2 phase in a dose-dependent manner (Figure 2.8C-E). In contrast, expression 
of Vpx had no effect on Vpr-mediated G2 arrest (Figure 2.8F-G). 
In order to determine if Vpr acted in a similar manner, 293FT cells were 
transfected with an HA-Vpx expressing plasmid alone or in the context of HA-Vpr at 2:1 
or 1:1. As expected, Vpx expression resulted in the depletion of SAMHD1 (Figure 2.9, 
lane 1 vs lane 2). In contrast to the inability of Vpx to relieve Vpr-mediated G2 arrest, co-
expression of Vpr robustly inhibited Vpx-induced SAMHD1 degradation (Figure 2.9, 
lanes 3 and 4 vs lane 2). 
 These observations, taken together, support a model in which Vpr and Vpx bind 
DCAF1 in a competitive manner. These observations cannot distinguish whether this 
competition is for a shared binding site, to which Vpr binds more tightly, or binding to an 
allosteric site. However, we favor a model in which Vpr and Vpx utilize a similar binding 
interface on DCAF1 based on the high homology between their third α-helix, known to 
be the major determinant of DCAF1 binding (Le Rouzic et al., 2007; Srivastava et al., 
2008; Schwefel et al., 2014)(reviewed in (Morellet et al., 2009)). In agreement with the 
hypothesis that Vpr has higher affinity for this binding domain, no mutations to the 
  
56 
DCAF1 WD40 domain were identified which abrogated Vpr binding (Table 2.1, data not 
shown, and Figure 2.6). 
 
Vpr but not Vpx enhances the DCAF1 interaction with DDB1 
 It has recently been reported that co-IP of some DCAF1 mutants with DDB1 is 
enhanced in the presence of Vpr (Gérard et al., 2014). Examining our own co-IPs, we 
observed a similar phenomenon, whereby Vpr enhanced interaction between WT DCAF1 
and DDB1 (Figure 2.10a, lanes 3 and 4). Based on the observed difference between Vpr 
and Vpx with respect to their interaction with DCAF1, we were curious as to the effect of 
Vpx on the DCAF1-DDB1 interaction. Expression of Vpx had no apparent effect on the 
DCAF1-DDB1 interaction (Figure 2.10b lanes 2 and 4). 
 
Discussion 
 While several studies have examined the molecular determinants on Vpr and Vpx 
for DCAF1 interaction, little is known in regards to the residues in DCAF1 that mediate 
these interactions. In this study, we generated a series of point mutations to the previously 
described Vpr minimal binding domain of DCAF1 (the WD40 domain) (Le Rouzic et al., 
2007) and screened them for their ability to mediate Vpr and Vpx interaction and 
function. Surprisingly, although Vpx and Vpr share a high degree of homology in their 
DCAF1 binding motifs, we observed differential effect of these mutations on their ability 
to facilitate Vpr and Vpx interaction. Two DCAF1 WD40 mutations, N1135A and 
W1156H, were identified which failed to co-IP with Vpx. These residues were recently 
identified as being involved in the coordination of the Vpx Q76 residue, the mutation of 
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which is known to abrogate DCAF1 binding (Srivastava et al., 2008), in a recently 
resolved Vpx-DCAF1(WD40)-SAMHD1 co-crystal (Schwefel et al., 2014). While we 
would expect these residues to coordinate the analogous Vpr Q65, their mutation does not 
abrogate binding with Vpr. 
 This difference may be due in part to different binding affinities of Vpr and Vpx 
for DCAF1. To address this hypothesis, we conducted a functional competition assay 
between Vpr and Vpx. In support of the hypothesis that Vpr binds DCAF1 with higher 
affinity than Vpx, expression of Vpr was able to inhibit the degradation of SAMHD1 by 
Vpx, though the reciprocal relationship was not observed. Furthermore, expression of 
Vpr, but not Vpx, was seen to enhance the interaction between DCAF1 and DDB1. While 
we favor a model in which Vpr binds more tightly to DCAF1 than Vpx, our observations 
do not exclude the possibility that Vpr and Vpx utilize different binding interfaces on 
DCAF1. More thorough biochemical analysis will be necessary to fully distinguish 
between these two possibilities. 
 Recent studies have highlighted the therapeutic potential of targeting HIV-1 
accessory gene function (Stanley et al., 2012; Wei et al., 2014; Nekorchuk et al., 2013; 
Hofmann et al., 2013). While these studies are promising proofs of concept, a more 
thorough understanding of the molecular architecture of the ubiquitin ligases in the 
context of viral manipulation will be necessary to develop more specific pharmacological 
inhibitors. Disruption of Vpr activity is a compelling avenue for future drug development. 
The presence of Vpr among all primate lentiviruses indicate a strong selective pressure 
for Vpr function of viral pathogenesis. Indeed, in vivo studies in a rhesus macaque model 
of AIDS indicated a delayed onset of disease in monkeys infected with Vpr-deficient 
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viruses (Lang et al., 1993; Hoch et al., 1995). In addition, retrospective analysis of a 
vaccine study conducted in chimpanzees in which two animals were challenged with a 
Vpr-deficient HIV revealed reversion of the defective Vpr reading frame in both animals 
(Goh et al., 1998)(Reviewed in (Andersen et al., 2008)). The highly conserved natures of 
the Vpr/Vpx DCAF1 binding motif (Srivastava et al., 2008), as well as that of DCAF1 
(Zhang et al., 2008) present a novel target for future drug development, for which the 












Figure 2.1 DCAF1 domain architecture 










Figure 2.2: DCAF1 truncations DDB1 co-IP 
293FT cells were transfected with plasmids expressing Flag-DCAF1 or the truncations 
described. Cell lysates were subject to Flag-immunoprecipation and analyzed for the 
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Table 2.1: DCAF1 mutations summary 
DCAF1 Mutations were screened for their ability to facilitate Vpx-mediated SAMHD1 
degradation. Truncation and select point mutants were screened for Vpr function and 
interaction with Vpx/Vpr/DDB1. Blanks represent mutant not tested for that particular 
interaction/function. 
 Function Interaction 
 SAMHD1 Deg G2 Arrest Vpr Vpx DDB1 
Iso1 Yes Yes Yes Yes Yes 
Iso3 No   Yes Yes Yes 
dWD40 No   No Yes No 
dAcid No   No Yes No 
dWD40-dAcid No   No No No 
Arm-Iso1 No   No Yes No 
Arm-Iso3 No   No No No 
Lish-WD40 No No Yes Yes Yes 
dArm No No Yes No Yes 
WD40 No No Yes No No 
WD40-Acid No No Yes No No 
Acid  No    
dLish No No No No No 
D1092A No No Yes Yes Yes 
H1134A Yes Yes Yes Yes Yes 
N1135A No No Yes No Yes 
T1141A Yes    Yes    
T1155A Yes    Yes     
W1156H No No Yes No Yes 
E1178A-D1179A Yes    Yes     
H1180A Yes    Yes     
K1196A Yes    Yes     
N1221A-N1222A Yes    Yes     
R1225A Yes    Yes     
N1226A Yes    Yes     
D1256A Yes No Yes Yes Yes 
K1257A Yes    Yes     
S1263A Yes    Yes     
D1295A Yes    Yes     
Q1296A Yes    Yes     
Q1316A Yes    Yes     
D1320A Yes    Yes     
F1334Y Yes    Yes     
V1350T Yes    Yes     









Figure 2.3: DCAF1 mutation strategy 
A) DCAF1 WD40 domain and WDR5 protein sequences were aligned using ClustW2 
(Larkin et al., 2007). WDR5 tertiary structure is indicated below (bold lines – β-sheets, 
narrow lines connect β-sheets which form respective “blades” of the β-propeller. 
Homology is indicated below, asterisks (*) indicate identity, colons (:) and periods (.) 
similarity. Purple arrowheads indicate residues mutated in DCAF1. B) ModBase (Pieper 
et al., 2014) predicted structure of the DCAF1 WD40 domain. Residues mutated in our 
screen are highlighted in purple. 
  
A.
DCAF1           ---------EDESGFTCCAFSARERFLMLGTCTGQLKLYNVFSGQEEASYNCHNSAITHL
WDR5            NYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDV
                            ...:.  **..  :*  .:.   :*::..:.*: * : . *: .*: :
DCAF1           EPSRDGSLLLTSATWSQPLSALWGMKSVFDMKHSFTEDHYV---EFSKHSQDRVIGTKGD
WDR5            AWSSDSNLLVSAS--DDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDE
                  * *..**::::  .:    :*.:.*   :*     .:**   :*. :*:  * *: .:
DCAF1           IAHIYDIQTGNKLLTLFNPDLANNYKRNCATFNPTDDLVLN---DGV--LWDVRSAQAIH
WDR5            SVRIWDVKTGKCLKTL----PAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLK
                 ..*:*::**: * **     *:.   ... **  ..*::.   **:  :**. *.*.::
DCAF1           KF-DKFNMNISGV-FHPNGLEVIINT-----EIWDLRTFHLLHTVPALDQCRVVFNHTGT
WDR5            TLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFS
                .: *. *  :* * * ***  ::  *     ::**  . : *:* .. .: .  :  . :
DCAF1           VMYGAMLQADDEDDLMEERMKSPFGSSFRTFNATDYKPIATIDVKRNIF--DLCTDTKDC
WDR5            VTGGKWIVSGSEDNLV------------YIWNLQTKEIVQKLQGHTDVVISTACHPTENI
                *  *  : :..**:*:              :*    : : .:: : ::.    *  *:: 
DCAF1           YLAVIENQGSMDALNMDTVCRLYEVGRQRLAEDEDE
WDR5            IASA--------ALENDKTIKLWK---------SDC
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Figure 2.4: Analysis of DCAF1 mutations for their ability to facilitate Vpx-mediated 
SAMHD1 degradation  
Cells were transfected with human Myc-SAMHD1, HA-Vpx, and/or Flag-DCAF1 
mutant expression plasmids as indicated. 36 hr posttransfection cells were lysed and 















Figure 2.5: Analysis of DCAF1 truncations and point mutant ability to interact with Vpx 
293FT cells were transfected with plasmids expressing Flag-DCAF1 mutations and HA-
Vpx as indicated. Cell lysates were subject to Flag-immunoprecipation and analyzed for 
the presences of HA-Vpx by Western blot. 
  








Figure 2.6: DCAF1 determinants of Vpr interaction are different than those of Vpx 
293FT cells were transfected with plasmids expressing Flag-DCAF1 mutations and HA-
Vpr as indicated. Cell lysates were subject to Flag-immunoprecipation and analyzed for 
the presences of HA-Vpr by Western blot. 
  












Figure 2.7: DCAF1 WD40 mutants inhibit Vpr induced G2 arrest 
HeLa cells were transfected with DCAF1 mutants or empty vector control plasmids and 



































































Figure 2.8: Vpx fails to compete Vpr mediated G2 arrest 
Cells were transduced with control (GFP) or Vpr expressing virus alone or with Vpx or 
the dominant negative Vpr R80A and analyzed for G2 arrest by FACS. Infection ratios 






















Figure 2.9: Vpr functions dominantly to Vpx 
293FT cells were transfected with a HA-Vpx plasmid in the presence or absence of a 
HA-Vpr expression plasmid. All cells were transfected with equal amounts of total 
plasmid DNA by transfection of pcDNA3.1. Cells were lysed 36 hr posttransfection and 
endogenous SAMHD1 levels were analyzed by Western blot. 
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ANALYSIS OF THE STRUCTURAL DETERMINANTS OF G2 ARREST AND 
SAMHD1 DEGRADATION BY THE SIV(AGM) VPR 
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Abstract 
The HIV-1 accessory protein Vpr is known to induce G2 arrest by manipulating 
the Cul4-DDB1-DCAF1 ubiquitin ligase, inducing the ubiquitination of Mus81. 
Induction of cell cycle arrest by Vpr is conserved among primate lentiviruses. In addition 
to Vpr, a subset of primate lentiviruses encode the Vpr paralog Vpx, which functions to 
enhance myeloid cell infection by inducing the degradation of the restriction factor 
SAMHD1. Interestingly, some Vpr homologs, namely SIVagm Vpr, are bifunctional, 
able to induce G2 arrest and the degradation of SAMHD1. To better understand the 
structure-function relationship between HIV-1 Vpr and SIVagm Vpr, we generated 
several HIV-1 Vpr truncations and chimeras between these two proteins. We tested the 
ability of these chimeric proteins to induce G2 arrest in human cells and degrade 
SAMHD1. From our analyses, we conclude that substitution of the C-terminal 
unstructured region of SIVagm Vpr by the same region of HIV-1 Vpr confers to this 
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chimera the de novo ability to arrest human cells in G2. In addition, while the N-terminal 
domain of SIV Vpx was shown to be important for degradation of SAMHD1, we show 
additional determinants are necessary for this activity. Finally, the ubiquitination target 
for HIV-1 Vpr was recently reported to be Mus81. While we confirm that HIV-1 Vpr 
induces degradation of Mus81 in a proteasome- and Cullin-dependent manner, our results 
indicate that this function is independent of the ability of Vpr to induce G2 arrest. 
 
Introduction 
 The primate lentiviral protein Vpr is conserved among all primate lentiviruses 
(HIV/SIV). Studies of other mammalian lentiviruses have identified Vpr-like genes in 
several evolutionarily distant lentiviruses pointing to an ancient origin for Vpr function 
(R\reviewed in (Gifford, 2012)). Vpr expression of has been shown to induce a pleotropic 
number of effects including increased infection of nondividing cells, involvement in pre-
integration complex nuclear import (Heinzinger et al., 1994), and the manipulation of the 
Cul4-DCAF1 ubiquitin ligase facilitating degradation of UNG2 (Schröfelbauer et al., 
2005) (reviewed in (Andersen et al., 2008)) and induction of G2 cell cycle arrest (Dehart 
et al., 2007; Le Rouzic et al., 2007; Wen et al., 2007; Hrecka et al., 2007; Belzile et al., 
2007; Schröfelbauer et al., 2007) through the activation of the endonuclease SLX4 
complex (Laguette et al., 2014). 
 In addition to Vpr, a subset of primate lentiviruses encode the highly related 
protein, Vpx (Gifford, 2012). Evolutionary studies indicate it arose following a gene 
duplication event in the most recent common ancestor of the SIVs infecting the 
Cercopithecinae tribe Popionini (SIVmnd/mac/smm) (Lim et al., 2011)(reviewed in 
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(Planelles, 2011)). Although Vpr and Vpx share a high degree of structural homology 
(Tristem et al., 1990) they exert functionally distinct roles in viral replication, 
suppression of interferon response (Laguette et al., 2014), and infection of myeloid cells 
by inducing the degradation of SAMHD1 (Laguette et al., 2011; Hrecka et al., 2011) 
(Reviewed in (Laguette and Benkirane, 2012)), respectively. Interestingly, the SIVs 
which infect the five genetically distinct African Green Monkey (AGM) species, 
collectively referred to as SIVagm, encode a single Vpr gene capable of inducing both 
G2 arrest and SAMHD1 degradation (reviewed in (Planelles, 2011)).  
In addition to their distinct functionality, Vpr and Vpx have undergone 
evolutionary arms races (reviewed in (Duggal and Emerman, 2012)), resulting in a 
species-specific ability to antagonize their respective restriction factors. While HIV-1 
Vpr is able to induce cell cycle arrest in cells from several primate species, SIVagm Vpr 
activities (both the induction of cell cycle arrest and the degradation of SAMHD1) are 
known to be restricted to antagonism of the AGM restriction factor homologs (Planelles 
et al., 1996; Lim et al., 2011). 
In this study, we aim to understand the molecular determinants of G2 arrest and 
SAMHD1 degradation, respectively. To this end, we generated a number of HIV-1 Vpr- 
SIVmac Vpx and HIV-1 Vpr – SIVagm Vpr chimeras. While early studies have 
demonstrated the necessity of the unstructured N and C-terminus for SAMHD1 
degradation (Gramberg et al., 2010) and G2 arrest induction (Le Rouzic et al., 2007; 
Morellet et al., 2009), respectively, it remains unclear if additional determinants are 
necessary to mediate these functions.  
Here we demonstrate that simple transposition of Vpr or Vpx unstructured termini 
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onto the reciprocal paralog is not sufficient to confer neofunctionality to the chimeric 
proteins, indicating Vpr and Vpx function are not defined by simple linear determinants. 
In further support of this hypothesis, we observe that the transposition of the SIVagm Vpr 
C-terminus onto HIV-1 Vpr retained the ability to induce G2 arrest in human cells. 
Finally, we explore the link between Vpr G2 arrest and the degradation of the newly 
identified Vpr target Mus81, a subcomponent of the SLX4 complex, recently described as 
being ubiquitinated in a Vpr-dependent manner (Laguette et al., 2014). In contrast, we 
observe Mus81 to be degraded by Vpr in a G2 arrest and DCAF1-independent manner. 
 
Materials and Methods 
Cell culture 
Exponentially growing 293FT and HeLa cells were cultured in Dulbecco minimal 
essential medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) and 1% L-glutamine (Invitrogen). 293FT cells were transfected 
using the Calcium Phosphate method, as previously described (Zhu et al., 2001). 36 hr 
posttransfection, cells were harvested, washed 2x with Phosphate Buffered Saline (PBS), 
and lysed as described below. HeLa cells were transfected with the FuGene HD 
(Promega, Madison, WI) per manufacturer’s protocol. Cells were treated, when indicated, 
with 0.5 µM Epoxomicin (SIGMA-ALDRICH) or 100 nM MLN4924 (MedChem 







pFIN-EF1-GFP-2A-mCherry-WPRE vector was kindly provided by Susan L. 
Semple-Rowland. MluI and EcoRV restriction sites were added to this vector by site-
directed mutagenesis using the QuikChange Lightning (Agilent Technologies). HIV-1 
Vpr, SIVagm Vpr, and SIVmac Vpx were PCR amplified with MluI and EcoRV 
restriction sites added to the primer, and cloned into pFIN-EF1-GFP-2A-mCherry-WPRE 
in place of mCherry. Chimeras were generated by PCR and and cloned into pFIN-EF1-
GFP-2A-mCherry-WPRE using MluI and EcoRV restriction sites. cDNA for Mus81 was 
purchased from DNASU (Tempe, AZ). Mus81 was PCR amplified and N-terminus 
tagged with V5 epitope. V5-Mus81 was cloned into pFIN-EF1-GFP-2A-mCherry-WPRE 
in place of GFP using NheI and BspeI restriction sites. A stop codon was added before 
the 2A generating into pFIN-EF1-V5-Mus81. HA-AGM-SAMHD1 was kindly provided 
by M. Emerman. 
 
Immunoprecipitation and Western blots 
For immunoprecipitation, cells were gently detached by incubation in PBS and 
pelleted at 13,000 rpm for 5 min in a tabletop microcentrifuge. Cells were lysed with Flag 
IP buffer (50 mM Tris HCI, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% TRITON X-
100) in the presence of protease inhibitors (Complete EDTA free tablets; Roche, 
Indianapolis, IN). Lysate protein concentrations were determined by Pierce™ BCA 
(Thermo Scientific, Rockford, IL) and brought to equal protein concentration. Lysates 
were subject to immunoprecipitation using Anti-FLAG® M2 Magnetic Beads (SIGMA-
ALDRICH, St. Louis, MO) in accordance to manufacturer recommendations. Briefly, 
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lysates were incubated with beads for 2 hr (at RT) to overnight (at 4ºC). Beads were 
washed 5x with lysis buffer and proteins eluted with 3x-FLAG® Peptide, 100 µg/ml for 1 
hr at RT. Cells for degradations assays were lysed in SET Buffer (1% SDS, 50mM Tris 
HCL, pH 7.4, 1mM EDTA); lysates were thoroughly denatured by boiling for 5 min. 
Lysates and immunoprecipitation samples were resolved by SDS-PAGE on 4-10% 
Criteron™ TGX™ gels (Bio Rad, Hercules, CA) per manufacturer’s recommendations 
and transferred to PVDF membrane (EMD Millipore, Billerica, MA). The following 
antibodies were used: FLAG® M2 and β-actin (Sigma Aldrich), HA.11 and 9E11(c-
Myc)(Covance), DDB1 (Abcam) and V5 (Life Technologies, Carlsbad, CA) 
 
Lentiviral vectors 
pFIN GFP-2A-HIV-1 Vpr, pFIN GFP-2A-SIVmac Vpx, pFIN GFP-2A-SIVagm 
Vpr, and pFIN GFP viruses were produced as previously described (Zimmerman et al., 
2004; Roshal et al., 2003). Briefly, 293FT cells were transfected as described earlier with 
transfer vector, pCMV ∆8.2∆Vpr packaging plasmid, and pCMV-VSVG envelope 
plasmid at a ratio of 2.5:2.5:1. Supernatants were collected every 24 hr, until the cell 
monolayer died. Cell debris was cleared by centrifugation at ~825x-g for 5 min. Pooled 
supernatant was concentrated by ultracentrifugation at 25,000x-g for 2 hr. Concentrated 
virus was resuspended in DMEM with 10% FBS and 1% L-Glutamine and stored at -
80ºC. HeLa cells were transduced in the presence of 10µg/ml polybrene overnight. 





FACS and cell cycle analysis 
HeLa cells were detached by trypsinization and washed in fluorescence-activated 
cell sorting (FACS) buffer (2% FBS and 0.02% Sodium Azide in PBS). For analysis of 
GFP+, cells were immediately subject to flow cytometry. Cells for cell cycle analysis 
were pelleted at ~825x-g for 5 min and fixed with 70% ethanol at -20ºC overnight. Fixed 
cells were rehydrated by two washes in PBS. DNA content was determined by staining in 
50µg/ml propidium iodide in 0.1% Triton X-100 PBS with RNase A for 20 min. Cells 
were analyzed on a BD FACS Canto II flow cytometer using the FACSDiva software 




HIV-1 Vpr unstructured C-terminus is necessary for the induction of G2 arrest 
It was previously proposed that the C-terminus unstructured region of HIV-1 Vpr 
is required to recruit the G2 arrest targeted protein (Di Marzio et al., 1995)(Reviewed in 
(Morellet et al., 2009)). Furthermore, the point mutant Vpr R80A, although able to 
interact with DCAF1, is unable to induce G2 arrest, resulting in a dominant negative 
phenotype by competing for DCAF1 binding (Dehart et al., 2007; Le Rouzic et al., 2007). 
To directly test for the presence of an essential G2 arrest determinant within the C-
terminus unstructured region of HIV-1 Vpr, we made two truncations in HIV-1 Vpr 
(Vpr1-80 and Vpr1-84) and tested for their ability to induce G2 arrest in human cells. 
HeLa cells were transfected with empty vector, HIV-1 Vpr, HIV-1 Vpr R80A, HIV-1 
Vpr (1-80), or HIV-1 Vpr (1-84). 48 hr posttransfection cell cycle was analyzed by flow 
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cytometry. As shown in Figure 3.1, HIV-1 Vpr, but not HIV-1 Vpr R80A, HIV-1 Vpr (1-
80), nor HIV-1 Vpr (1-84), was able to arrest the cell cycle in G2. 
 
Unstructured termini are not sufficient to facilitate neofunctionality  
of monofuctional Vpr or Vpx 
 A NMR structure of Vpr revealed that it is comprised of a tight three α-helical 
bundle flanked by unstructured N- and C-termini (Morellet et al., 2003). Alignment of 
Vpr and Vpx show high homology between the two proteins within these α-helices 
(Figure 3.2, grey boxes), while the termini are divergent. These observations have led to 
the hypothesis that substrate specificity of Vpr and Vpx is defined by these unstructured 
termini. In agreement with this hypothesis, previous studies indicate that mutations 
disrupt the Vpr-induced G2 arrest cluster in the C-terminal unstructured region of Vpr 
(Morellet et al., 2009). The N-terminus of Vpx has been shown to be necessary for 
recruitment of SAMHD1 for degradation (Gramberg et al., 2010). Interestingly, 
alignment of the bifunctional SIVagm Vpr reveals it to have high homology with Vpx in 
the N-terminus, while its C-terminus (with the exception of a poly-proline stretch shared 
with Vpx) is homologous to that of Vpr. These observations led us to hypothesize that 
transposition of these domains would result in the generation of chimeric proteins capable 
of mediating both SAMHD1 degradation and inducing G2 arrest. In order to test this 
hypothesis, we generated a series of HIV-1 Vpr/SIVagm Vpx chimeras in which the 





In order to determine if the monofunctional proteins had acquired an additional 
function confeered by grafting the corresponding N or C terminal domains from a 
heterologous protein, resulting in a bifunctional protein capable of both inducing G2 cell 
cycle arrest and SAMHD1 degradation (reminiscent of the bifunctionality observed in 
SIVagm Vpr), HeLa cells were transduced with lentiviruses expressing full length HIV-1 
Vpr, SIVmac Vpx, or chimeric proteins. Transduced cells were analyzed for G2 arrest by 
flow cytometry (Figure 3.4A). As expected, expression of HIV-1 Vpr induced a robust 
accumulation of cells in the G2 phase, while SIVmac Vpx had no effect on the cell cycle 
profile compared to uninfected cells. Transposition of SIVmac Vpx N-terminus onto 
HIV-1 Vpr (X1-22 R16-96) had only modest, if any, effect on the induction of G2 arrest, 
indicating that the Vpr G2 arrest determinants are either not present within the N-terminal 
region, or these residues are conserved within the N-terminus of SIVmac Vpx. 
Transposition of the C-terminus of HIV-1 Vpr onto SIVmac Vpx (X1-88R78-96) did not 
confer G2 arrest functionality to this chimera. These observations indicate that Vpr G2 
arrest determinants are not linear and localized only within the unstructured C-terminal 
region. This is in agreement with previous observations in which mutations to the linker 
region between the second and third α-helix were able to abrogate Vpr-induced G2 arrest 
(reviewed in (Morellet et al., 2009)). Finally, lysates of transduced cells were analyzed 
for the ability of WT or chimeric proteins to induce the degradation of SAMHD1. 
Transposition of the putative functional determinant domain (SIVmac Vpx N-terminus) 
failed to confer SAMHD1 degradation to X1-22 R16-96. In contrast, both WT SIVmac Vpx 





Understanding the molecular determinants of species-specific G2 arrest 
 To study the structure-function relationships in HIV-1 Vpr and SIVagm Vpr, a set 
of 6 chimeras were constructed as shown in Figure 3.5. The exchange points for these 
chimeras were designed based on the published NMR structure of HIV-1 Vpr (Morellet et 
al., 2009) and were intended to maintain the predicted secondary structure of the parental 
proteins. In order to address the contribution of the poly-proline domain (PPD), which is 
present at the C-terminus of SIVagm Vpr but not HIV-1 Vpr, we generated a SIVagm 
Vpr truncation without the PRD (ΔP). 
To test whether the chimeras maintained the capacity to fold correctly, we 
verified their ability to interact with the well-established cellular partner, DCAF1. 293FT 
cells were transfected with pCDNA (empty vector control), HIV-1 Vpr, SIVagm Vpr, 
chimeras, or HIV-1 Vpr Q65R that is unable to interact with DCAF1 (Dehart et al., 2007; 
Le Rouzic et al., 2007). 48 hr posttransfection cells were harvested, lysed, and 
immunoprecipitated (IP) with anti-HA antibody. As expected, HIV-1 Vpr and SIVagm 
Vpr were able to Co-IP with DCAF1, while Vpr Q65R was not able to interact with 
DCAF1, as previously reported. All chimeras were able to interact with DCAF1 (data not 
shown), indicating they were capable of properly folding. 
 
The unstructured C-terminal region of HIV-1 Vpr is sufficient to confer  
upon SIVagm Vpr the ability to induce G2 arrest in human cells 
 While HIV-1 Vpr is able to induce cell cycle arrest in human and nonhuman 
primate cells, SIVagm Vpr was observed to only arrest AGM cells (Planelles et al., 
1996). We hypothesized that grafting the C-terminus unstructured region of HIV-1 Vpr 
  
86 
onto SIVagm Vpr would confer upon SIVagm Vpr the de novo ability to induce G2 arrest 
in human cells. HeLa cells were transduced with HA-HIV-1 Vpr, HA-SIVagm Vpr, or 
chimera expressing lentiviral vectors. In agreement with this prediction, transposition of 
the C-terminus unstructured region of HIV-1 Vpr onto SIVagm Vpr (chimera 1) 
conferred the ability to induce G2 arrest in human cells (Figure 3.6). Surprisingly, 
transposition of the C-terminus unstructured region of SIVagm onto Vpr HIV-1 Vpr 
(chimera 2) resulted in a chimera that retained the ability to induce cell cycle arrest in 
human cells, although to a lesser degree when compared with HIV-1 Vpr. These results 
indicate that recruitment of the G2 arrest substrate is dependent on residues outside the 
unstructured C-terminus. This is in agreement with previous results which identified 
several residues within the linker region between the second and third α-helices 
(reviewed in (Morellet et al., 2009)). Alignment of HIV-1 Vpr and SIVagm Vpr show a 
high degree of homology between these proteins within this region, as well as within the 
3 α-helices, indicating additional determinants may be present elsewhere within HIV-1 
Vpr and SIVagm Vpr. Surprisingly, transposition of the entire third α-helix alone 
(chimera 6) or with C-terminus of HIV-1 Vpr onto SIVagm Vpr (chimera 5) abrogated 
the ability of this chimera to induce G2 arrest. Whether this is due to an inability to 
recruit G2 arrest substrate or improper folding will require further analysis. 
 
Degradation of agmSAMHD1 by SIVagm Vpr requires the N and  
C-terminal domains of SIVagm Vpr 
In order to determine the domains in SIVagm Vpr that are important to target 
agmSAMHD1 for degradation, we tested whether the chimeras between SIVagm Vpr and 
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HIV-1 Vpr could degrade agmSAMHD1. 293FT cells were co-transfected with HA-
agmSAMHD1 and vectors encoding HA-HIV-1 Vpr, HA-SIVagm Vpr, or chimeras. 36 
hr posttransfection cells were harvested and the expression of exogenous agmSAMHD1 
was analyzed by Western blot. In agreement with previous reports (Lim et al., 2011), 
agmSAMHD1 was degraded by SIVagm Vpr (Figure 3.7, lanes 5) but not by HIV-1 Vpr 
(Figure 3.7 lane 4). The N-terminal domain of SIVmac Vpx was previously suggested to 
be required to overcome SAMHD1 restriction in myeloid cells (Gramberg et al., 2010). 
Therefore, we expected that transfer of the HIV-1 Vpr C-terminal unstructured region 
onto SIVagm Vpr would not affect SAMHD1 degradation. Surprisingly, this chimera was 
unable to facilitate the degradation of agmSAMHD1 (Figure 3.7, lane 5). This result 
indicates that the SIVagm Vpr C-terminus is necessary for the degradation of SAMHD1; 
however, transposition of this domain onto HIV-1 Vpr (chimera 2) did not confer the 
ability to degrade SAMHD1. This suggests that in the context of HIV-1 Vpr, SIVagm 
Vpr C-terminus is not sufficient to induce SAMHD1 degradation (Figure 3.7, lane 6). In 
agreement with our earlier observations of HIV-1 Vpr/SIVmac Vpx chimeras, the N-
terminus of SIVagm Vpr was necessary, but not sufficient for the degradation of 
agmSAMHD1 (Figure 3.7, Lane 4 vs 7 and 8). 
 
HIV-1 Vpr-induced degradation of Mus81 is independent of the 
induction of G2 arrest 
The SLX4 complex was recently identified as the G2 arrest target of HIV-1 Vpr 
(Laguette et al., 2014). In the presence of Vpr, Mus81 is ubiquitinated, contributing to the 
activation of this complex, leading to G2/M arrest. Although Laguette et al. observed a 
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Vpr-dependent ubiquitination of Mus81, they propose a model in which this promotes the 
activation of the SLX4 complex (Laguette et al., 2014)(reviewed in (Cohen, 2014)). This 
is in contrast to earlier models that proposed Vpr-mediated G2 arrest was induced 
through the degradation of a cellular factor (Dehart et al., 2007; Le Rouzic et al., 2007; 
Schröfelbauer et al., 2007; Hrecka et al., 2007; Belzile et al., 2007; Wen et al., 
2007)(reviewed in (Andersen et al., 2006). Based on this difference, we wished to further 
explore the effect of Vpr on Mus81. In agreement with Laguette and colleagues, we 
observe a Vpr-dependent destabilization of Mus 81 (Figure 3.8). 
We then asked whether degradation of Mus81 correlated with the ability of Vpr 
induce G2 arrest. 293FT cells were co-transfected with V5-Mus81 and HIV-1 Vpr, HIV-
1 Vpr R80A, or HIV-1 Vpr Q65R. 48 hr posttransfection cells were lysed and levels of 
Mus81 were analyzed by Western blot. As shown in Figure 3.9, HIV-1 Vpr induced 
degradation of Mus81 (Figure 3.9 compare lanes 3 and 4). Surprisingly, HIV-1 Vpr 
R80A (Figure 3.9 compare lanes 3 and 11) and HIV-1 Vpr Q65R (compare lane 3 and 
15), two mutants that fail to induce G2 arrest, also degrade Mus81. This observation 
indicates that the destabilization of Mus81 is independent of the ability of Vpr to induce 
G2 arrest or manipulate the Cul4-DCAF1 ubiquitin ligase. Interestingly, inhibition of the 
proteasome with epoxomicin, or the more specific inhibition of Cullin-based ubiquitin 
ligases with MLN4924 (Soucy et al., 2009), resulted in the stabilization of Mus81 in the 
presence of HIV-1 Vpr (Figure 3.9, lane 4 vs lanes 7 and 8). These observations 
demonstrate that the destabilization of Mus81 by Vpr is an ubiquitination and Cullin 
family ubiquitin ligase-dependent activity. 
Recently, expression of Vpr has been shown to result in large changes to the 
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cellular ubiquitin ligase pathway (Arora et al., 2014). In order to determine if Mus81 
destabilization was merely due to modulation of the UPS by Vpr, we examined the effect 
of the highly related SIVmac Vpx and SIVagm Vpr on Mus81 stability. To this end, cells 
were transfected with V5-Mus81 and SIVmac Vpx or SIVagm Vpr. In contrast to HIV-1 
Vpr (Figure 3.10, lane 3 vs 4), neither SIVmac Vpx or SIVagm Vpr induced degradation 
of V5-Mus81 (Figure 3.10, lanes 6 and 12, respectively). Taken together, these results 
point to a model whereby Vpr specifically induces the degradation of Mus81 in a Cullin 
ubiquitin ligase-dependent, G2 arrest-independent manner. 
 
Discussion 
 Vpr is a highly conserved accessory protein encoded by all primate lentiviruses 
and found in all primary isolates of HIV-1 (reviewed in (Andersen et al., 2006)). 
Although the exact function of Vpr remains unclear, expression of Vpr is known to 
induce cell cycle arrest at the G2 phase, putatively through the activation of the SLX4 
complex, in order to inhibit induction of an interferon response to viral reverse tanscripts 
(Laguette et al., 2014). In addition to Vpr, some primate lentiviruses are known to encode 
the paralogous Vpx, involved in mediating infection of myeloid cells through the 
degradation of SAMHD1 (Laguette et al., 2011; Hrecka et al., 2011)(Reviewed in 
(Planelles, 2011)). Interestingly, the SIV species that infect AGM encode a Vpr that is 
able to induce G2 arrest and degradation SAMHD1, in a species-specific manner. This 
bifunctional Vpr, as well as evolutionary studies (Lim et al., 2011; Laguette et al., 2012), 
support a model whereby Vpr acquired SAMHD1 antagonism before the “birth” of the 
monofunctional Vpx. While the exact evolutionary event leading to the “birth” of Vpx 
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remains controversial, sustaining antagonism against two cellular proteins may have been 
too evolutionarily difficult (Planelles, 2012). In this study, we examine the structural 
determinants of G2 arrest and SAMHD1 degradation by Vpr and its homologs.  
 Previous studies have demonstrated the necessity of the unstructured N and C-
termini of Vpx and Vpr for their function, respectively (Le Rouzic et al., 2007; Ahn et al., 
2012). While we had hypothesized that transfer of these domains between HIV-1 Vpr and 
SIVmac Vpx would confer neofunctionality on the respective chimeric proteins, we 
observe that the molecular determinants of Vpr G2 arrest and Vpx SAMHD1 degradation 
involve residues outside of these regions. In agreement with this observation, a recently 
resolved crystal structure of DCAF1(WD40)-Vpx-SAMHD1(C-terminal domain) 
demonstrated that residues located within the linker between the second and third α-helix 
of Vpx are involved in the recruitment of SAMHD1 (Schwefel et al., 2014). 
 In order to gain a better understanding of the molecular determinants of G2 arrest 
and SAMHD1 degradation, we generated a second set of chimeras between HIV-1 Vpr 
and the more closely related SIVagm Vpr. In contrast to SIVmac Vpx, SAMHD1 
degradation by SIVagm Vpr was abrogated by transposition of either HIV-1 Vpr N or C-
terminus. This differential requirement of SIVagm Vpr C-terminus for SAMHD1 
degradation may be in part explained by the recently described toggling of the 
determinant on SAMHD1 for lentiviral antagonism (Fregoso et al., 2013). Even within 
the closely related AGM species, the residues on SAMHD1 and SIVagm Vpr that 
mediate their interaction are under strong evolutionary pressure (Spragg and Emerman, 
2013). 
In contrast to SAMHD1 degradation, the species-specific induction of G2 arrest 
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by SIVagm Vpr was more amenable to modulation. Indeed, while WT SIVagm Vpr is 
unable to induce cell cycle arrest in human cells (Planelles et al., 1996), transposition of 
the HIV-1 Vpr C-terminus onto SIVagm Vpr conferred the ability to induce G2 arrest in 
human cells. While the C-terminus of Vpr is known to be necessary for the induction of 
G2 arrest (this work and (Le Rouzic et al., 2007)), the SIVagm Vpr C-terminus is able to 
restore G2 arrest activity of these HIV-1 Vpr truncations. These observations support a 
hypothesis whereby Vpr-mediated G2 arrest is dependent on a nonlinear determinant 
within the protein. This observation indicates that the determinants leading to species-
specific induction of G2 arrest by Vpr are located outside of this region. To fully resolve 
the molecular mechanisms of Vpr activity will require further biochemical analysis.  
 Finally, we examine the connection of G2 arrest with the recently described Vpr 
ubiquitination target, Mus81 (Laguette et al., 2014). In contrast to what Laguette and 
colleagues report, we observe Mus81 degradation to be independent of Vpr induction of 
G2 arrest. Indeed, the G2 arrest defective Vpr mutant, R80A, is able to induce the 
degradation of Mus81. Additionally, this activity appears to be independent of Vpr 
manipulation of the Cul4-DCAF1 ubiquitin ligase as Vpr Q65R, which is unable to 
interact with DCAF1, also induces degradation of Mus81. Finally, we observed that the 
degradation of Mus81 by Vpr is dependent on a Cullin ubiquitin ligase, as the 
neddylation inhibitor MLN4924 inhibits Mus81 degradation by Vpr. Further study will 
be necessary to elucidate the exact mechanism by which Vpr exerts this function. We 
have previously observed Vpr to interact with Cul1 (unpublished results), whether Vpr 
modulates the activity of an additional ubiquitin ligase towards the destabilization of 












Figure 3.1 HIV-1 Vpr C-terminal unstructured terminus is necessary  
for the induction of G2 arrest  
HeLa cells were transfected with empty control vector, Vpr or truncations as indicated. 




















































































































































































































































































































































































































































































































Figure 3.3 Schematic of HIV-1 Vpr/SIVmac Vpx chimeras 
Chimeric Vpr/Vpx proteins were generated through the transposition of Vpr C-terminus 
and Vpx N-terminus as indicated. Proteins are comprised of residues of Vpr or Vpx, 




















Figure 3.4 Cell cycle analysis of HIV-1 Vpr/SIVmac Vpx chimeras 
HeLa cells were transduced with lentiviral vectors expressing WT Vpr/Vpx or chimeras 
as indicated. Viruses were tittered by expression of the reporter protein GFP, percentages 
indicated in parenthesis above histograms. A) G2 arrest compared by ratio of G2/G1 as 
indicated. B) SAMHD1 degradation by HIV-1 Vpr, SIVmac Vpx, and chimeras was 
























Figure 3.5 Schematic of HIV-1 Vpr/SIVagm Vpr chimeras 
Chimeric HIV-1 Vpr/SIVagm Vpr proteins were generated through the transposition of 
regions as indicated. Subscript numbers represent residues of originating protein. Barrels 
represent α-helices based on the Vpr NMR structure (Morellet et al., 2009), and SIVagm 





















































































































































































































































































































































































































































































































































Figure 3.8 Vpr induces the degradation of Mus81  
293FT cells were transfected with 1.0µg, 0.5µg or 0.1µg of V5-Mus81 and HA-Vpr as 
indicated. 48 hr posttransfection cells were lysed and analyzed for the degradation of 
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Current Views on Vpr and Vpx Biology 
 In the thirty years since the discovery of HIV as the causative agent of AIDS, 
researchers have intensely investigated the mechanisms of pathogenesis. The ~9kb HIV 
genome encodes 9 genes and 15 proteins. While the major function of nearly all of these 
proteins have been well elucidated over the ensuing decades, the small 96-aa accessory 
protein, Vpr, has remained largely enigmatic (Guenzel et al., 2014). Early studies 
revealed Vpr to be a virion-associated protein involved in infection of nondividing cells 
and enhancement of transcription from the viral promoter (reviewed in (Emerman, 
1996)). Vpr was shown to induce cell cycle arrest at the G2/M transition through the 
activation of the ssDNA damage sensor ATR (Roshal et al., 2003); however, the 
importance of this biology has remained unclear.  
Perhaps the first real clue to the role of Vpr in HIV-1 replication came following 
the determination that it modified the activity of a cellular ubiquitin ligase comprised of 
Cul4-DDB1-DCAF1 (Cul4-DCAF1) (Dehart et al., 2007; Le Rouzic et al., 2007; Wen et 
al., 2007; Hrecka et al., 2007; Schröfelbauer et al., 2007) (reviewed in (Andersen et al., 
2008; Guenzel et al., 2014)). Manipulation of cellular ubiquitin ligases is a mechanism 
common to numerous viruses to induce the degradation of cellular restriction factors 
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(Randow and Lehner, 2009). Indeed, 2 additional HIV accessory proteins, Vif and Vpu 
are known to alter the specificity of the UPS (Collins and Collins, 2014). These 
observations lead to the hypothesis that Vpr was subverting the Cul4-DCAF1 ubiquitin 
ligase to induce the degradation of an as of yet unidentified host protein involved in 
inhibiting HIV replications. Recently, Laguette et al. reported Vpr induced the 
ubiquitination of Mus81, triggering the activation of the SLX4 complex, as the long 
sought after Vpr G2 arrest target (Laguette et al., 2014); however, our results call this 
observation into question. In addition to Vpr, a subset of primate lentiviruses (including 
SIVmac and HIV-2), are known to encode Vpx, a Vpr paralog, thought to have arisen 
following a gene duplication event, necessary for the efficient infection of myeloid cells 
through the Cul4-DCAF1-mediated degradation of SAMHD1 (Laguette et al., 2011; 
Hrecka et al., 2011)(Reviewed in (Planelles, 2011)).  
 
New insights into the differential manipulation of Cul4-DCAF1 
by Vpr and Vpx 
 In this work, we explore the molecular mechanisms by which Vpr and Vpx 
manipulate the Cul4-DCAF1 ubiquitin ligase and exert their function. Vpr and Vpx are 
both known to form a tight 3 α-helical bundle flanked by unstructured N and C-termini 
(Morellet et al., 2009; Schwefel et al., 2014). While a highly conserved motif located in 
the third α-helix has been shown to be necessary for the interaction of Vpr and Vpx with 
DCAF1, little is know about the molecular determinants within DCAF1 that facilitate this 
interaction (Le Rouzic et al., 2007). To this end, we generated a number of DCAF1 
truncations and point mutants in order to define this interaction. Surprisingly, although 
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the residues of Vpr and Vpx involved in DCAF1 are highly homologous we observe 
differential interaction of these viral proteins with DCAF1. Most notably, mutations to 
DCAF1 N1135 and W1156 abrogate Vpx binding, while they had no effect on the 
interaction with Vpr. A recently solved DCAF1(WD40)-Vpx-SAMHD1(Ctd) co-crystal 
identified these residues as being involved in coordinating Vpx Q76, mutation of which 
was previously shown to abrogate Vpx-DCAF1 interaction (Le Rouzic et al., 2007; 
Schwefel et al., 2014). While the exact cause of these differences will require more 
thorough biochemical analysis, based on the high homology and conservation of the 
Vpr/Vpx DCAF1 binding motif, we favor a model in which Vpr binds DCAF1 with 
higher affinity than Vpx. 
 To examine this hypothesis, we tested the effect of Vpr expression on Vpx-
mediated SAMHD1 degradation. In agreement with a model in which Vpr binds DCAF1 
more tightly than Vpx, we observed that Vpr was able to robustly compete Vpx function. 
In contrast, while the dominant negative Vpr R80A mutant was able to inhibit Vpr 
induction of G2 arrest, expression of Vpx had no effect. 
 In addition, we explore the molecular determinants within Vpr and Vpx that 
facilitate the recruitment of their respective targets. Previous studies have identified the N 
and C-terminal unstructured regions of Vpx and Vpr, respectively, for the degradation of 
SAMHD1 and induction of G2 arrest (Ahn et al., 2012; Le Rouzic et al., 2007); however, 
these observations were made in the context of truncations. Interestingly, while Vpr and 
Vpx are known to be “monofunctional” proteins, inducing cell cycle arrest or mediating 
SAMHD1 degradation, a subset of primate lentiviruses (SIVagm) encode a bifunctional 
Vpr capable of facilitating both functions. To further elucidate the molecular 
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determinants of Vpr and Vpx function, we generated a series of chimeric proteins by 
transposing the unstructured regions of HIV-1 Vpr and SIVmac Vpx as wells as between 
HIV-1 Vpr and the bifunctional SIVagm Vpr. These studies revealed additional residues 
outside of the unstructured N and C-termini mediate Vpr and Vpx function. This is in 
agreement with a recently published crystal structure of DCAF1(WD40)-Vpx-
SAMHD1(Ctd), in which residues within the linker region mediate interaction between 
Vpx and SAMHD1 (Schwefel et al., 2014). This observation was further confirmed by 
the loss of agmSAMHD1 degradation ability of all HIV-1 Vpr/SIVagm Vpr chimeras. 
Surprisingly, the species-specific ability to induce G2 arrest appears to have arisen by 
compensatory mutations in both the Vpr α-helical bundle as well as the unstructured C-
terminus. More refined study of the evolution and structure of Vpr will be necessary to 
identify the specific residues involved in mediating Vpr interaction with the G2 arrest 
target. 
 Finally, Laguette and colleagues recently reported the activation of the SLX4 
endonuclease complex, through the ubiquitination of Mus81, by Vpr as the causative 
mechanism of Vpr G2 arrest (Laguette et al., 2014). In contrast to their observations, we 
demonstrate that the G2 arrest-defective Vpr mutants Vpr Q65R and Vpr R80A are both 
capable of inducing degradation of Mus81. To verify that Mus81 degradation is not 
simply an indirect effect of DCAF1 manipulation, we examined the ability of SIVmac 
Vpx and SIVagm Vpr, both capable of binding human DCAF1 but unable to induce G2 
arrest in human cells. Unlike HIV-1 Vpr, neither of these homologs were able to induce 
Mus81 degradation. The exact mechanism by which Vpr causes the destabilization of 
Mus81 remains unclear; however, pharmacological inhibition of the Cullin ubiquitin 
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ligase family with MLN4924 inhibited Vpr-induced Mus81 degradation. The discrepancy 
between the observations of Laguette et al. and our own concerning Vpr-mediated Mus81 
will require further investigation. These studies raise important questions regarding the 




Cul4 ubiquitin ligases and manipulation by other viral proteins 
 In addition to HIV/SIV, several other viruses have been observed to manipulate 
Cul4-based ubiquitin ligases (Table 1.1). While the effect of SV5 V-protein manipulation 
of the Cul4-DDB1 complex has been thoroughly studied (reviewed in (Barry and Früh, 
2006)), the functional role in viral replication of other viral Cul4 manipulators remains 
largely unclear. Perhaps most interesting is the recent observation that the UL35 protein 
of cytomegalovirus triggers G2 arrest by interaction with Cul4-DCAF1, reminiscent of 
Vpr activity. Interestingly, several members of the SLX4 complex (SLX4, ERCC1 and 
ERCC4, but not MUS81 or EME1) were identified as UL35 interactors by mass 
spectrometry (Salsman et al., 2012). Whether UL35 activates the SLX4 complex as Vpr 
does is yet to be resolved; however, this observation lends credence to the hypothesis that 
SLX4 activation may be a strategy utilized by multiple viruses to avoid recognition of 
exogenous nucleic acids and the subsequent induction of an interferon response. 
 In addition to primates, lentiviruses have been identified as infectious agents in a 
large number of mammals including rabbits, horses, cows, and wild and domestic cats. 
Genetic studies have identified Vpr-like genes in a large number of these lentiviruses 
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(reviewed in (Gifford, 2012)). While the study of many of these viruses has generally 
been quite limited, studies in FIV indicate viral-mediated SLX4 complex activation may 
be quite old evolutionarily. While the exact function of FIV Vpr ortholog, OrfA, remains 
unresolved, expression of OrfA has been shown to induce G2 cell cycle arrest (among 
other phenotypes). OrfA protein sequence alignment with Vpr shows a high degree of 
homology between the two proteins. Of particular note, the DCAF1 binding motif of Vpr 
is nearly identical (Gemeniano et al., 2004). Although it is currently unknown if OrfA 
manipulates the UPS in general, or Cul4-DCAF1 specifically, the high conservation of 
DCAF1 (particularly of the WD40 domain) from humans to Arabidopsis (Zhang et al., 
2008) supports the hypothesis that Cul4-DCAF1 manipulation may be common 
throughout lentiviruses. 
 
Targeting accessory gene function as a therapeutic 
 Current antiretroviral therapies have focused on directly targeting viral enzymatic 
function. To date, these strategies have proven to be effective; however, they suffer from 
several drawbacks, even in comparison to antibiotics. Namely, antivirals currently in use 
have suffered from two major drawbacks: 1) modern antivirals are generally effectively 
against very limited ranges of virus (“one drug/one bug”) and 2) high rates of mutations, 
especially in RNA viruses, has been observed to lead to rapid resistance to antivirals 
(reviewed in (Volberding and Deeks, 2010; Lou et al., 2014)). To this end, it has been 
proposed that targeting cellular factors necessary for viral replication may provide an 
avenue for the development of drugs with a broader range and a higher evolutionary 
barrier to escape (reviewed in (Coley et al., 2009; Linero et al., 2012)). 
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 While accessory genes are not required for viral replication in some in vitro 
systems, viruses lacking these genes are severely hindered during in vivo infection 
(reviewed in (Malim and Emerman, 2008; Malim and Bieniasz, 2012)). Manipulation of 
Cullin-based ubiquitin ligases by a large number of viruses (table 1) make identification 
of pharmacological modulators of Cullin activity a compelling putative antiviral target. A 
recently identified small molecule inhibitor of Cullin activation currently in phase I 
clinical trials as a potential cancer therapy, MLN4924 (Soucy et al., 2009; 2010), is a 
compelling proof of concept for the antiviral potential of inhibiting accessory protein 
function.  
Cullin activity is dependent on the autoconjugation of the ubiquitin like modifier 
NEDD8 to the Cullin, facilitating later substrate ubiquitination by inducing 
conformational changes within the Cullin. Cullin neddylation follows an analogous 
pathway to cellular protein ubiquitination, in which NEDD8 is activated in an ATP-
dependent manner by the NEDD8 activating enzyme (NAE) followed by transfer to an 
E2 and finally conjugation to the Cullin (Saha and Deshaies, 2008; Duda et al., 
2008)(reviewed in (Soucy et al., 2010; Saifee and Zheng, 2008)). MLN4924 functions as 
an AMP analogue with high specificity for NAE, inhibiting NEDD8 activation, and 
subsequently specifically inhibits Cullin activity (Soucy et al., 2009). Indeed, the clinical 
effectiveness of UPS inhibition in cancer treatment has already been demonstrated 
following the recent approval of proteasome inhibitor bortezomib (VELCADE) (Soucy et 
al., 2010).  
 To this end, several groups have demonstrated the antiviral potential of Cullin 
inhibition by MLN4924. In 2012, Stanley et al. demonstrated that MLN4924 treatment 
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inhibited Vif-mediated APOBEC3 degradation, mimicking infection of ∆Vif virus, 
allowing for APOBEC3 encapsidation into budding virions and induction of 
hypermutation of the HIV-genome (Stanley et al., 2012b). In addition, MLN4924 has 
been shown to inhibit Vpx-mediated SAMDH1 degradation, resulting in the inhibition of 
myeloid cell infection even in the presence of Vpx (Wei et al., 2013; Hofmann et al., 
2013; Nekorchuk et al., 2013). Finally, inhibition of neddylation appears to inhibit Vpu-
mediated CD4 degradation and Vpr-mediated Mus81 degradation (Chapter 3). It will be 
of great interest to determine if similar effects are observed in the context of viral 
infections in vivo. 
 While MLN4924 serves as a strong proof of concept for the antiviral effects of 
directly targeting cellular proteins, resulting in the inhibition of accessory protein 
function, further research will be necessary before similar therapeutic strategies will be 
effective clinically. While MLN4924 specially targets Cullin based ubiquitin ligases, 
without broadly effecting cellular protein turnover, it has been shown to exert robust 
cytotoxic effects (Soucy et al., 2009). While such cytopathies may be acceptable in 
cancer treatments, for which MLN4924 is in clinical trials, they may be less well 
tolerated in the treatment pathogens, such as HIV. Further insight into the molecular 
architecture of virally hijacked ubiquitin ligases may provide even more specific targets 
for future chemotherapeutic targeting. Indeed, manipulation of Cul5 by Vif provides one 
such example. While two unique NEDD8 E2s have been identified, UBE2F and UBE2M 
(UBC12), Cul5 has been shown to be uniquely, among Cullins, neddylated by UBE2F 
(reviewed in(Soucy et al., 2010)). To this end, Stanley and collogues observed Vif-
mediated APOBEC3 degradation to be UBE2F dependent (Stanley et al., 2012a). 
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Understanding the specific architectural features of ubiquitin ligases manipulated by viral 
proteins holds great promise for the development of future broad range antivirals.  
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